

Schedule 1

**UNITED STATES BANKRUPTCY COURT
SOUTHERN DISTRICT OF NEW YORK**

In re:	:	Chapter 11
	:	
PURDUE PHARMA L.P., <i>et al.</i> ,	:	Case No. 19-23649 (RDD)
	:	
Debtors. ¹	:	(Jointly Administered)
	:	

**SECOND MONTHLY FEE STATEMENT OF KPMG LLP FOR COMPENSATION
FOR SERVICES RENDERED AND REIMBURSEMENT OF EXPENSES
INCURRED AS TAX CONSULTANT FOR THE DEBTORS
AND THE OFFICIAL COMMITTEE OF UNSECURED CREDITORS
FOR THE PERIOD FROM FEBRUARY 1, 2020 THROUGH FEBRUARY 29, 2020**

Name of Applicant:	KPMG LLP
Authorized to Provide Professional Services to:	The Debtors and the Official Committee of Unsecured Creditors
Date of Retention:	February 24, 2020, <i>nunc pro tunc</i> to December 23, 2019
Period for Which Compensation and Reimbursement is Sought:	February 1, 2020 through February 29, 2020
Amount of Compensation Sought as Actual, Reasonable, and Necessary:	\$ 449,728.00
Less 20% Holdback:	\$ (89,945.60)
Amount of Expense Reimbursement Sought as Actual, Reasonable, and Necessary:	\$ 522.22
Total Fees and Expenses Due:	\$ 360,304.62

¹ The Debtors in these cases, along with the last four digits of each Debtor's registration number in the applicable jurisdiction, are as follows: Purdue Pharma L.P. (7484), Purdue Pharma Inc. (7486), Purdue Transdermal Technologies L.P. (1868), Purdue Pharma Manufacturing L.P. (3821), Purdue Pharmaceuticals L.P. (0034), Imbrium Therapeutics L.P. (8810), Adlon Therapeutics L.P. (6745), Greenfield BioVentures L.P. (6150), Seven Seas Hill Corp. (4591), Ophir Green Corp. (4594), Purdue Pharma of Puerto Rico (3925), Avrio Health L.P. (4140), Purdue Pharmaceutical Products L.P. (3902), Purdue Neuroscience Company (4712), Nayatt Cove Lifescience Inc. (7805), Button Land L.P. (7502), Rhodes Associates L.P. (N/A), Paul Land Inc. (7425), Quidnick Land L.P. (7584), Rhodes Pharmaceuticals L.P. (6166), Rhodes Technologies (7143), UDF L.P. (0495), SVC Pharma L.P. (5717) and SVC Pharma Inc. (4014). The Debtors' corporate headquarters is located at One Stamford Forum, 201 Tresser Boulevard, Stamford, CT 06901.

Dated: April 2, 2020

/s/ Howard Steinberg

Howard Steinberg

Partner, KPMG LLP

1350 Avenue of the Americas

New York, New York 10019

(212) 872-6562

EXHIBIT A

Purdue Pharma, L.P.

Case No. 19-23649

Summary Of Hours and Discounted Fees Incurred By Professional
February 1, 2020 through February 29, 2020

Professional Person	Position & Department	Country of Origin	Total Billed Hours	Hourly Billing Rate	Total Compensation
Ankit Mohan	Senior Manager - Tax	India	0.7	\$ 578	\$ 404.60
Arpit Desai	Senior Manager - Tax	UK	6.5	\$ 750	\$ 4,875.00
Ashley Armfield	Senior Associate - M&A Tax	US	121.5	\$ 534	\$ 64,881.00
Carlotta Bertu	Senior Associate - Tax	Italy	4.0	\$ 640	\$ 2,560.00
Casey Nunez	Senior Manager - M&A Tax	US	11.7	\$ 744	\$ 8,704.80
Christin Witt	Manager - German Intl' Tax	US	5.7	\$ 650	\$ 3,705.00
Claudio Mengotti	Manager - Tax	Switzerland	12.1	\$ 730	\$ 8,833.00
Courtney Alonzo	Senior Associate - Intl' Tax	US	20.3	\$ 534	\$ 10,840.20
Dawn Krishnamurthy	Manager - M&A Tax	US	15.2	\$ 695	\$ 10,564.00
Denis Larkin	Principal - Tax	Australia	4.7	\$ 566	\$ 2,660.20
Devon Rowles	Associate - M&A Tax	US	105.9	\$ 350	\$ 37,065.00
Diego Lipp	Senior Associate - Tax	Switzerland	16.0	\$ 640	\$ 10,240.00
Frank Caratzola	Senior Associate - Intl' Tax	US	5.0	\$ 534	\$ 2,670.00
Gavin Little	Managing Director - Tax	UK	2.0	\$ 985	\$ 1,970.00
Hanah Lewis	Senior Associate - Tax	Australia	8.0	\$ 239	\$ 1,912.00
Henrique Palm	Managing Director - Tax	Brazil	2.0	\$ 985	\$ 1,970.00
Howard Steinberg	Partner - M&A Tax	US	7.5	\$ 856	\$ 6,420.00
Isaac Hirsch	Managing Director - Int'l Tax	US	34.2	\$ 819	\$ 28,009.80
Jess Commisso	Associate - M&A Tax	US	154.4	\$ 350	\$ 54,040.00
Justin Davis	Partner - Tax	Australia	0.9	\$ 655	\$ 589.50
Karl Tong	Manager - Tax	China	1.1	\$ 594	\$ 653.40
Kevin Broich	Senior Manager - M&A Tax	US	3.2	\$ 744	\$ 2,380.80
Lorenzo Bellavite	Partner - Tax	Italy	1.1	\$ 985	\$ 1,083.50
Madeleine Latham	Associate - Tax	UK	7.0	\$ 380	\$ 2,660.00
Maggie Scully	Associate - M&A Tax	US	11.2	\$ 350	\$ 3,920.00
Marissa Low	Manager - Tax	Singapore	7.4	\$ 730	\$ 5,402.00
Mark Hoffenberg	Principal - Washington National Tax	US	3.5	\$ 980	\$ 3,430.00
Michael Land	Senior Associate - M&A Tax	US	65.5	\$ 534	\$ 34,977.00
Monica Plangman	Associate Director - Bankruptcy	US	7.5	\$ 264	\$ 1,980.00
Nick Morgan	Associate - M&A Tax	US	49.4	\$ 350	\$ 17,272.50
Nicolas Meer	Paraprofessional - Tax	Switzerland	8.9	\$ 295	\$ 2,625.50
Pascal von Ah	Senior Associate - Tax	Switzerland	0.8	\$ 640	\$ 480.00
Paul Harden	Managing Director - Tax	UK	1.5	\$ 985	\$ 1,477.50
Paul Kunkel	Senior Manager - Washington National Tax	US	3.5	\$ 744	\$ 2,604.00
Pete DiMatteo	Manager - Int'l Tax	US	44.0	\$ 650	\$ 28,600.00
Philipp Reer	Partner - German Intl Tax	US	1.6	\$ 765	\$ 1,224.00
Radhika Rastogi	Senior Manager - Tax	India	3.7	\$ 469	\$ 1,735.30
Sayan Basak	Associate - Tax	Singapore	17.0	\$ 380	\$ 6,460.00
Simon Juon	Partner - Tax	Switzerland	2.0	\$ 985	\$ 1,970.00
Sonia Stricker	Associate - Tax	Germany	7.0	\$ 380	\$ 2,660.00
Thomas Giordano	Associate - Int'l Tax	US	136.7	\$ 350	\$ 47,845.00
Thomas Heubach	Senior Manager - Tax	Germany	1.5	\$ 750	\$ 1,125.00
Tracy Stone	Principal - Washington National Tax	US	8.7	\$ 906	\$ 7,882.20

EXHIBIT A

Purdue Pharma, L.P.

Case No. 19-23649

Summary Of Hours and Discounted Fees Incurred By Professional
February 1, 2020 through February 29, 2020

Professional Person	Position & Department	Country of Origin	Total Billed Hours	Hourly Billing Rate	Total Compensation
Urs Kipfer	Senior Manager - Tax	Switzerland	1.1	\$ 750	\$ 825.00
Wendy Shaffer	Manager - Bankruptcy	US	37.6	\$ 202	\$ 7,595.20
Zafer Ülgen	Associate - Tax	Netherlands	9.1	\$ 380	\$ 3,458.00
Less 50% Rate Reduction related to Non-Working Travel Time					\$ (1,228.50)
Subtotal of Hours and Discounted Fees			979.8		\$ 454,011.50
Credit related to updated KPMG India rates in KPMG's 1st monthly fee application (Exhibit C1)					\$ (3,055.00)
Less KPMG Voluntary Reduction related to Non-Working Travel Time					\$ (1,228.50) ⁽¹⁾
Total Discounted Fees					\$ 449,728.00
Total Out of Pocket Expenses					\$ 665.31
Voluntary Reduction in Expenses					\$ (143.09)
Total Out of Pocket Expenses After Voluntary Reduction					\$ 522.22 ⁽²⁾
Total Fees and Out of Pocket Expenses					\$ 450,250.22
Less Holdback Adjustment (20%)					\$ (89,945.60)
Net Requested Fees & Out of Pocket Expenses					\$ 360,304.62
Blended Hourly Rate				\$ 459.00	

⁽¹⁾ KPMG is taking a voluntary reduction of non-working travel time.

⁽²⁾ See Exhibit D and D1 for an explanation of the expenses and the voluntary reduction.

EXHIBIT B

Purdue Pharma, L.P.

Case No. 19-23649

Summary of Hours and Discounted Fees Incurred by Category
February 1, 2020 through February 29, 2020

Category	Exhibit	Total Billed Hours	Total Fees Requested
Bankruptcy Tax Consulting Services	C1	931.7	\$ 440,152.80
Non -Working Travel Time	C2	3.0	\$ - ⁽¹⁾
Retention Services	C3	0.6	\$ 158.40
Fee Application Preparation Services	C4	44.5	\$ 9,416.80
Total		979.8	\$ 449,728.00

⁽¹⁾ KPMG is taking a voluntary reduction of non-working travel time.

EXHIBIT C1

Purdue Pharma, L.P.

Case No. 19-23649

Bankruptcy Tax Consulting Services
February 1, 2020 through February 29, 2020
(includes time not previously billed)

Name	Date	Description	Hours	Rate	Amount
Carlotta Bertu	01/27/20	Discussion with L. Bellavite and C. Bertù (both KPMG Italy) on the outcome of the review of FY 2016, 2017 and 2018 audited financial statements of Mundipharma Pharmaceuticals S.r.l.	0.5	\$ 640	\$ 320.00
Lorenzo Bellavite	01/27/20	Discussion with L. Bellavite and C. Bertù (both KPMG Italy) on the outcome of the review of FY 2016, 2017 and 2018 audited financial statements of Mundipharma Pharmaceuticals S.r.l.	0.5	\$ 985	\$ 492.50
Lorenzo Bellavite	01/27/20	Performed Partner review of the email response to J. Commisso (KPMG US) - prepared by C. Bertù (KPMG Italy) detailing results of review of financial statements (from an Italian tax perspective).	0.6	\$ 985	\$ 591.00
Carlotta Bertu	01/27/20	Drafting (0.9) and sending (0.1) the email response to J. Commisso (KPMG US), detailing the outcome of the review of FY 2016, 2017 and 2018 audited financial statements of Mundipharma Pharmaceuticals S.r.l.	1.0	\$ 640	\$ 640.00
Carlotta Bertu	01/27/20	Review of FY 2016 (0.9), 2017 (0.7) and 2018 (0.9) audited financial statements of Mundipharma Pharmaceuticals S.r.l.	2.5	\$ 640	\$ 1,600.00
Radhika Rastogi	02/01/20	Discussion with A. Mohan (KPMG India) on the findings of the tax features of the Indian entities of Mundipharma International Limited group and pending information required	0.7	\$ 469	\$ 328.30
Ankit Mohan	02/01/20	Discussion with R. Rastogi (KPMG India) on the findings of the tax features of the Indian entities of Mundipharma International Limited group and pending information required	0.7	\$ 578	\$ 404.60
Radhika Rastogi	02/01/20	Analyzed the audited financial statements (Financial Year 2016-2018) (1.5), and performed a senior manager review of information summary prepared by N. Gupta, N. Jain and A. Kakar (all KPMG)(1.0)	2.5	\$ 469	\$ 1,172.50
Radhika Rastogi	02/02/20	Drafting initial email response to J. Commisso (KPMG-US) capturing the pending information / master file covering the tax features for the evaluated entities for India.	0.5	\$ 469	\$ 234.50
Pete DiMatteo	02/02/20	Drafted PowerPoint slide deck depicting proposed stock/asset sale of a specific German subsidiary.	2.4	\$ 650	\$ 1,560.00
Pete DiMatteo	02/02/20	Drafted PowerPoint slide deck depicting proposed stock/asset sale of a specific UK subsidiary	2.6	\$ 650	\$ 1,690.00
Devon Rowles	02/03/20	Correspondence via email with KPMG Australia member firm regarding next steps related to review of new financial statements provided by client as of 2/3/20	0.3	\$ 350	\$ 105.00
Michael Land	02/03/20	Reviewed court docket (Prime Clerk) to identify additional tax filings as of 2/3/2020.	0.4	\$ 534	\$ 213.60

EXHIBIT C1

Purdue Pharma, L.P.

Case No. 19-23649

Bankruptcy Tax Consulting Services

February 1, 2020 through February 29, 2020

(includes time not previously billed)

Name	Date	Description	Hours	Rate	Amount
Devon Rowles	02/03/20	(.8) Updating member firm master information list to include additional member firm countries added as of 2/3 to ensure accurate/update to date tracking of all information received to date	0.8	\$ 350	\$ 280.00
Thomas Giordano	02/03/20	Updates to the structure deck disposition scenarios for Mundipharma Medical Company Limited based on feedback from P. DiMatteo (KPMG) related to entity structure	0.8	\$ 350	\$ 280.00
Howard Steinberg	02/03/20	Review of preliminary structure deck disposition scenarios (asset versus stock) for the UK Mundipharma Medical Company Limited.	1.0	\$ 856	\$ 856.00
Ashley Armfield	02/03/20	Meeting with I. Hirsch, P. DiMatteo, M. Land, A. Armfield (all KPMG) to discuss cash tax model with regards to preferred equity distributions	1.3	\$ 534	\$ 694.20
Isaac Hirsch	02/03/20	Meeting with I. Hirsch, P. DiMatteo, M. Land, A. Armfield (all KPMG) to discuss cash tax model with regards to preferred equity distributions	1.3	\$ 819	\$ 1,064.70
Michael Land	02/03/20	Meeting with I. Hirsch, P. DiMatteo, M. Land, A. Armfield (all KPMG) to discuss cash tax model with regards to preferred equity distributions	1.3	\$ 534	\$ 694.20
Pete DiMatteo	02/03/20	Meeting with I. Hirsch, P. DiMatteo, M. Land, A. Armfield (all KPMG) to discuss cash tax model with regards to preferred equity distributions	1.3	\$ 650	\$ 845.00
Michael Land	02/03/20	Review of Switzerland disposition scenarios for purposes of analyzing tax consequences of an asset or stock sale	1.3	\$ 534	\$ 694.20
Michael Land	02/03/20	Perform review of Canada disposition scenarios for purposes of analyzing tax consequences of an asset or stock sale	1.4	\$ 534	\$ 747.60
Jess Commisso	02/03/20	Continue, same day, to create assigned portion of illustrative structure deck based on Norton Rose sale computations of Mundipharma entities pursuant to sharing with our member firms for sale / tax analysis purposes.	1.6	\$ 350	\$ 560.00
Jess Commisso	02/03/20	Incorporated India financial statement analysis (of tax attributes, reserves and audits) into a combined file of all Member Firm entities pursuant to Mundipharma entity analysis.	1.6	\$ 350	\$ 560.00
Thomas Giordano	02/03/20	Updates to structure deck disposition scenarios for Mundipharma Limited based on feedback received from P. DiMatteo (KPMG) related to entity structure	1.7	\$ 350	\$ 595.00
Nick Morgan	02/03/20	1.2 Updated the client structure deck to depict the multi-step analysis of the sale of UK entity 1 in order to demonstrate potential tax consequences on sale; 0.6 Reviewed most recent tax return of UK entity 1 with focus on tax posture.	1.8	\$ 350	\$ 630.00

EXHIBIT C1

Purdue Pharma, L.P.

Case No. 19-23649

Bankruptcy Tax Consulting Services

February 1, 2020 through February 29, 2020

(includes time not previously billed)

Name	Date	Description	Hours	Rate	Amount
Ashley Armfield	02/03/20	Meeting with P. DiMatteo, I. Hirsch, M. Land, A. Armfield (all KPMG) to review the latest version of the cash tax model	1.8	\$ 534	\$ 961.20
Isaac Hirsch	02/03/20	Meeting with P. DiMatteo, I. Hirsch, M. Land, A. Armfield (all KPMG) to review the latest version of the cash tax model	1.8	\$ 819	\$ 1,474.20
Michael Land	02/03/20	Meeting with P. DiMatteo, I. Hirsch, M. Land, A. Armfield (all KPMG) to review the latest version of the cash tax model	1.8	\$ 534	\$ 961.20
Pete DiMatteo	02/03/20	Meeting with P. DiMatteo, I. Hirsch, M. Land, A. Armfield (all KPMG) to review the latest version of the cash tax model	1.8	\$ 650	\$ 1,170.00
Pete DiMatteo	02/03/20	Performed international tax manager review of slide deck depicting proposed transactions related to the proposed sale of a specific UK subsidiary.	2.1	\$ 650	\$ 1,365.00
Nick Morgan	02/03/20	1.0 Updated UK entity 1 structuring to demonstrate at what entity level the sales of the company's assets would occur, which has different tax implications; 1.2 Updated UK entity 1 structuring to demonstrate tax consequences of cash flows on the sale of stock.	2.2	\$ 350	\$ 770.00
Thomas Giordano	02/03/20	Updated structure deck disposition scenarios for Mundipharma Deutschland based on feedback received from P. DiMatteo (KPMG) related to entity structure	2.4	\$ 350	\$ 840.00
Isaac Hirsch	02/03/20	(1.4) Managing Director review of updates to cash tax model prepared by A. Armfield (KPMG); (1.2) Managing Director review of updates to tax consequences outline with regards to additional research performed - as prepared by P. DiMatteo (KPMG).	2.6	\$ 819	\$ 2,129.40
Ashley Armfield	02/03/20	2.9 Preparing for project team meeting to discuss updates to the cash tax model (preparing alternatives for various disposition scenarios).	2.9	\$ 534	\$ 1,548.60
Thomas Giordano	02/03/20	Updated the structure deck disposition scenarios based on feedback received from P. DiMatteo (KPMG) related to entity structure.	3.6	\$ 350	\$ 1,260.00
Devon Rowles	02/03/20	(3.7) Updating the information request list to note all provided by documents received in the virtual data room on Friday 1/31	3.7	\$ 350	\$ 1,295.00
Jess Commisso	02/03/20	Created assigned portion of illustrative structure deck, as of 2/3/2020, based on Norton Rose sale computations of Mundipharma entities pursuant to sharing with our member firms for sale / tax analysis purposes.	3.9	\$ 350	\$ 1,365.00
Nick Morgan	02/04/20	0.4 Reviewed International structure deck proposals while concurrently analyzing tax consequences.	0.4	\$ 350	\$ 140.00

EXHIBIT C1

Purdue Pharma, L.P.

Case No. 19-23649

Bankruptcy Tax Consulting Services

February 1, 2020 through February 29, 2020

(includes time not previously billed)

Name	Date	Description	Hours	Rate	Amount
Thomas Giordano	02/04/20	Updated excel slide deck exchange rate tracker to include additional provided by client data received as of 2/4/2020.	0.6	\$ 350	\$ 210.00
Claudio Mengotti	02/04/20	Performed initial high level review of data room, client structure and Swiss related potential tax aspects/issues - based on documents provided in data room to date.	0.7	\$ 730	\$ 511.00
Pascal von Ah	02/04/20	Performed Swiss VAT analysis / high-level assessment of potential VAT risks, VAT audits/ controversies, VAT provisions based on available financial statements - per inquiry from D. Rowles (KPMG US)	0.8	\$ 640	\$ 480.00
Michael Land	02/04/20	Review of Prime Clerk filings related to Purdue Pharma December 31, 2019 balance sheet to gain insight into the Debtors' financial position with respect to assets and liabilities	0.8	\$ 534	\$ 427.20
Thomas Giordano	02/04/20	Continue (from 2/3/2020) to update the structure deck disposition scenarios for Mundibiopharma Limited with respect to entity structure.	1.1	\$ 350	\$ 385.00
Urs Kipfer	02/04/20	Manager review of VAT analysis / high-level assessment of potential VAT risks, VAT audits/ controversies, VAT provisions based on available financial statements (as per inquiry by D. Rowles (KPMG US)	1.1	\$ 750	\$ 825.00
Devon Rowles	02/04/20	(1.6) Drafted list of all provided by client documentation received in the virtual data room since 1/31/2020 in preparation for upcoming call with Norton Rose	1.6	\$ 350	\$ 560.00
Pete DiMatteo	02/04/20	Performed international tax manager review and concurrently modify various Purdue structure decks with regards specific attention to anticipated U.S. federal income tax consequences associated with proposed transactions.	1.8	\$ 650	\$ 1,170.00
Ashley Armfield	02/04/20	Review of Project Malta volume 1 document dated December 19, 2019 to gain insight into tax posture of the company, including related party obligations, third party debt, proposed dispositions.	1.8	\$ 534	\$ 961.20
Pete DiMatteo	02/04/20	Performed international tax manager review of PowerPoint presentation depicting proposed transaction steps relating to contemplated stock/asset sale of a German subsidiary.	1.9	\$ 650	\$ 1,235.00
Ashley Armfield	02/04/20	Updated cash tax model for manager review comments, specifically related to treatment of preferred shareholders / intercompany accounts.	1.9	\$ 534	\$ 1,014.60
Devon Rowles	02/04/20	(2.1) Performed Partnership research in the internal revenue code for tax consequences regarding the disposition of my designated Mundipharma entities pursuant to finalizing the structure decks.	2.1	\$ 350	\$ 735.00

EXHIBIT C1

Purdue Pharma, L.P.

Case No. 19-23649

Bankruptcy Tax Consulting Services
February 1, 2020 through February 29, 2020
(includes time not previously billed)

Name	Date	Description	Hours	Rate	Amount
Devon Rowles	02/04/20	(2.1) Updates to the structure deck with regards to partnership research completed (on same day) to ensure tax consequences are accurate	2.1	\$ 350	\$ 735.00
Jess Commisso	02/04/20	Performed partnership research in the internal revenue code for tax consequences regarding the disposition of assigned portion of Mundipharma entities pursuant to finalizing the structure decks.	2.1	\$ 350	\$ 735.00
Pete DiMatteo	02/04/20	Performed international tax manager review of PowerPoint presentation depicting proposed transaction steps relating to contemplated stock/asset sale of a UK subsidiary	2.2	\$ 650	\$ 1,430.00
Jess Commisso	02/04/20	Performed research to confirm assumptions included in our cash tax model.	2.6	\$ 350	\$ 910.00
Ashley Armfield	02/04/20	Reviewed Project Malta volume 2 document dated December 19, 2019 to gain insight related to tax posture of the company, including related party obligations, third party debt, proposed dispositions.	2.8	\$ 534	\$ 1,495.20
Thomas Giordano	02/04/20	Continued (from 2/3/2020) updating the structure deck disposition scenarios for Napp Pharmaceutical Holdings Company with respect to entity structure.	2.9	\$ 350	\$ 1,015.00
Jess Commisso	02/04/20	Continue, from 2/3, to create assigned portion of illustrative structure deck based on Norton Rose sale computations of Mundipharma entities pursuant to sharing with our member firms for sale / tax analysis purposes.	3.1	\$ 350	\$ 1,085.00
Michael Land	02/04/20	Performed research related to certain tax credits with regards to the Purdue cash tax model	3.1	\$ 534	\$ 1,655.40
Thomas Giordano	02/04/20	Continue (from 2/3/2020) to update the structure deck disposition scenarios for Mundipharma Deutschland with respect to entity structure	3.9	\$ 350	\$ 1,365.00
Devon Rowles	02/05/20	Continue, from earlier in the day, to perform updates to the structure decks regarding Purdue Pharma Inc. (Canada) asset/stock dispositions including related tax consequences pursuant to consistency with other country structure decks	0.2	\$ 350	\$ 70.00
Claudio Mengotti	02/05/20	Manager review of VAT team comments in connection with certain Swiss tax issues - based on available financial statements (as per inquiry by D. Rowles (KPMG US))	0.3	\$ 730	\$ 219.00
Isaac Hirsch	02/05/20	Performed Managing Director review of latest updates to Purdue structure deck as of 2/5/2020 - as prepared by P. DiMatteo (KPMG)	0.8	\$ 819	\$ 655.20
Claudio Mengotti	02/05/20	Performed Manager review of Swiss corporate tax analysis / overview on tax reserves, open tax audits and tax attribute carryforwards based on available financial statements (as per inquiry by D. Rowles, KPMG US)	0.9	\$ 730	\$ 657.00
Michael Land	02/05/20	Review of structure deck with regards to asset disposition for purposes of analyzing tax consequences of an asset sale	1.1	\$ 534	\$ 587.40

EXHIBIT C1

Purdue Pharma, L.P.

Case No. 19-23649

Bankruptcy Tax Consulting Services
February 1, 2020 through February 29, 2020
(includes time not previously billed)

Name	Date	Description	Hours	Rate	Amount
Thomas Giordano	02/05/20	Additional updates to structure deck disposition scenarios for Napp Pharmaceutical Holdings Company based on feedback from P. DiMatteo (KPMG) as of 2/5/2020.	1.2	\$ 350	\$ 420.00
Thomas Giordano	02/05/20	Continue (from 2/3/2020) to update the structure deck disposition scenarios for Mundipharma Medical Company Limited with respect to entity structure	1.3	\$ 350	\$ 455.00
Diego Lipp	02/05/20	Performed Swiss tax analysis / overview based on available financial statements (as per inquiry by D. Rowles (KPMG US))	1.3	\$ 640	\$ 832.00
Pete DiMatteo	02/05/20	Perform international tax Manager review and concurrently revise PowerPoint deck depicting proposed transactions relating to contemplated sale of a specific UK subsidiary	1.5	\$ 650	\$ 975.00
Devon Rowles	02/05/20	(1.6) Creating a list of all provided by client documentation received in the virtual data room since 1/31/2020 in preparation for an upcoming call with Norton Rose	1.6	\$ 350	\$ 560.00
Nick Morgan	02/05/20	Review latest round of requests for updates to Purdue International Slide Deck provided by project team on 2/4/20 and concurrently draft questions/comments related to same.	1.7	\$ 350	\$ 595.00
Jess Commisso	02/05/20	Continued, from 2/4, to create assigned portion of illustrative structure deck based on Norton Rose sale computations of Mundipharma entities.	2.1	\$ 350	\$ 735.00
Pete DiMatteo	02/05/20	Drafted outline detailing certain potential tax deductions and concurrently performed research related to same (as needed).	2.1	\$ 650	\$ 1,365.00
Thomas Giordano	02/05/20	Revised updates from 2/4/2020 for the structure deck disposition scenarios for Mundibiopharma Limited based on feedback from team (i.e., P. DiMatteo)	2.1	\$ 350	\$ 735.00
Nick Morgan	02/05/20	Finished updates to slide deck structuring documentation to include tax consequences of liquidating distributions related to specific Purdue entity.	2.3	\$ 350	\$ 805.00
Pete DiMatteo	02/05/20	Draft an outline relating to permissibility certain tax deductions while concurrently performing research (as needed).	2.4	\$ 650	\$ 1,560.00
Dawn Krishnamurthy	02/05/20	Performed detailed manager review of data room information provided by Norton Rose from Jan 31- Feb 5th and concurrently cross checked to information tracker prepared by D. Rowles (KPMG) to manage information flow.	2.6	\$ 695	\$ 1,807.00
Ashley Armfield	02/05/20	Performed detailed review of Debtor's information brief to gain additional understanding as to Purdue's financial situation (court doc. #17)	3.1	\$ 534	\$ 1,655.40

EXHIBIT C1

Purdue Pharma, L.P.

Case No. 19-23649

Bankruptcy Tax Consulting Services
February 1, 2020 through February 29, 2020
(includes time not previously billed)

Name	Date	Description	Hours	Rate	Amount
Devon Rowles	02/05/20	(3.9) Making updates to the structure decks regarding Purdue Pharma Inc. (Canada) asset/stock dispositions including related tax consequences pursuant to consistency with other country structure decks	3.9	\$ 350	\$ 1,365.00
Thomas Giordano	02/05/20	Additional updates to structure deck disposition scenarios for Napp Pharmaceutical Holdings Company based on feedback from P. DiMatteo (KPMG) as of 2/5/2020.	3.9	\$ 350	\$ 1,365.00
Jess Commisso	02/05/20	Continued, from earlier in the day, to create assigned portion of illustrative structure deck based on Norton Rose sale computations of Mundipharma entities pursuant to sharing with our member firms for sale / tax analysis purposes.	3.9	\$ 350	\$ 1,365.00
Ashley Armfield	02/05/20	Updating the cash tax model asset versus stock sale considerations for the UK proposed disposition entities.	3.9	\$ 534	\$ 2,082.60
Arpit Desai	02/06/20	Continue meeting (same day) with M. Latham (KPMG UK) to analyze and concurrently discuss the tax computations for the Purdue UK companies in scope. <u>Note</u> : two individuals performed this task with regards to the large volume of material to analyze.	1.1	\$ 750	\$ 825.00
Madeleine Latham	02/06/20	Continue meeting (same day) with A. Desai (KPMG UK) to analyze and concurrently discuss the tax computations for the Purdue UK companies in scope. <u>Note</u> : two individuals performed this task with regards to the large volume of material to analyze.	1.1	\$ 380	\$ 418.00
Thomas Giordano	02/06/20	Updated excel conversion rate companion file to scenario decks with regards to consistency/structure of the disposition scenario planning decks	0.8	\$ 350	\$ 280.00
Dawn Krishnamurthy	02/06/20	Manager review of memorandum regarding certain potential tax deductions.	1.1	\$ 695	\$ 764.50
Ashley Armfield	02/06/20	Meeting with D. Krishnamurthy, A. Armfield, D. Rowles (all KPMG) to discuss changes to the structure deck related to Netherlands asset/stock dispositions and related tax consequences.	1.2	\$ 534	\$ 640.80
Dawn Krishnamurthy	02/06/20	Meeting with D. Krishnamurthy, A. Armfield, D. Rowles (all KPMG) to discuss changes to the structure deck related to Netherlands asset/stock dispositions and related tax consequences.	1.2	\$ 695	\$ 834.00
Devon Rowles	02/06/20	Meeting with D. Krishnamurthy, A. Armfield, D. Rowles (all KPMG) to discuss changes to the structure deck related to Netherlands asset/stock dispositions and related tax consequences.	1.2	\$ 350	\$ 420.00

EXHIBIT C1

Purdue Pharma, L.P.

Case No. 19-23649

Bankruptcy Tax Consulting Services

February 1, 2020 through February 29, 2020

(includes time not previously billed)

Name	Date	Description	Hours	Rate	Amount
Jess Commisso	02/06/20	Meeting with M. Land, J. Commisso, N. Morgan (all KPMG) to discuss changes to the structure deck related to Napp Pharmaceutical Holdings Ltd. (United Kingdom) asset/stock dispositions and related tax consequences	1.2	\$ 350	\$ 420.00
Michael Land	02/06/20	Meeting with M. Land, J. Commisso, N. Morgan (all KPMG) to discuss changes to the structure deck related to Napp Pharmaceutical Holdings Ltd. (United Kingdom) asset/stock dispositions and related tax consequences	1.2	\$ 534	\$ 640.80
Nick Morgan	02/06/20	Meeting with M. Land, J. Commisso, N. Morgan (all KPMG) to discuss changes to the structure deck related to Napp Pharmaceutical Holdings Ltd. (United Kingdom) asset/stock dispositions and related tax consequences	1.2	\$ 350	\$ 420.00
Jess Commisso	02/06/20	Meeting with M. Land, J. Commisso, N. Morgan (all KPMG) to discuss changes to the structure deck re Purdue Pharma Inc. (Canada) asset/stock dispositions and related tax consequences	1.3	\$ 350	\$ 455.00
Michael Land	02/06/20	Meeting with M. Land, J. Commisso, N. Morgan (all KPMG) to discuss changes to the structure deck re Purdue Pharma Inc. (Canada) asset/stock dispositions and related tax consequences	1.3	\$ 534	\$ 694.20
Nick Morgan	02/06/20	Meeting with M. Land, J. Commisso, N. Morgan (all KPMG) to discuss changes to the structure deck re Purdue Pharma Inc. (Canada) asset/stock dispositions and related tax consequences	1.3	\$ 350	\$ 455.00
Ashley Armfield	02/06/20	Meeting with K. Krishnamurthy, A. Armfield, D. Rowles (all KPMG) to discuss changes to the structure deck related to Swiss asset/stock dispositions and related tax consequences	1.3	\$ 534	\$ 694.20
Dawn Krishnamurthy	02/06/20	Meeting with K. Krishnamurthy, A. Armfield, D. Rowles (all KPMG) to discuss changes to the structure deck related to Swiss asset/stock dispositions and related tax consequences	1.3	\$ 695	\$ 903.50
Devon Rowles	02/06/20	Meeting with K. Krishnamurthy, A. Armfield, D. Rowles (all KPMG) to discuss changes to the structure deck related to Swiss asset/stock dispositions and related tax consequences	1.3	\$ 350	\$ 455.00
Nick Morgan	02/06/20	1.5 Reviewed completed portions of Purdue structure deck with respect to asset sales for all entities	1.5	\$ 350	\$ 525.00
Ashley Armfield	02/06/20	Senior associate review of structure deck updates provided by team as of 2/6/2020.	1.5	\$ 534	\$ 801.00

EXHIBIT C1

Purdue Pharma, L.P.

Case No. 19-23649

Bankruptcy Tax Consulting Services
February 1, 2020 through February 29, 2020
(includes time not previously billed)

Name	Date	Description	Hours	Rate	Amount
Jess Commisso	02/06/20	Continue, from earlier in the day, to create assigned portion of illustrative structure deck based on Norton Rose sale computations of Mundipharma entities pursuant to sharing with our member firms for sale and tax analysis purposes.	1.6	\$ 350	\$ 560.00
Thomas Giordano	02/06/20	Continue, from 2/5/2020, to update the structure deck disposition scenarios for Mundipharma Medical Company Limited based on feedback received to date.	1.7	\$ 350	\$ 595.00
Nick Morgan	02/06/20	Revised structure of all UK entities on the client structure deck with respect to the 8-step approach for depicting the various tax consequences between an asset sale and a stock sale of the UK entities.	1.7	\$ 350	\$ 595.00
Pete DiMatteo	02/06/20	Review and concurrently revise PowerPoint slide documentation depicting proposed alternative asset/stock sale scenarios of various UK and German subsidiaries, including anticipated US tax consequences.	1.9	\$ 650	\$ 1,235.00
Thomas Giordano	02/06/20	Continue, from 2/5/2020, to update the structure deck disposition scenarios for Napp Pharmaceutical Holdings Ltd. Based on feedback received to date.	2.1	\$ 350	\$ 735.00
Thomas Giordano	02/06/20	Continue, from 2/5/2020, to revise structure deck disposition scenarios for Mundibiopharma Limited based on feedback received to date.	2.2	\$ 350	\$ 770.00
Casey Nunez	02/06/20	Performed senior manager review of updated disposition structure deck for purposes of facilitating the cash tax model	2.2	\$ 744	\$ 1,636.80
Thomas Giordano	02/06/20	Revised structure deck disposition scenarios for Mundipharma Deutschland based on feedback received from P. DiMatteo (KPMG) as of 2/6/2020.	2.2	\$ 350	\$ 770.00
Pete DiMatteo	02/06/20	Performed analysis regarding certain potential tax deductions in various contemplated structures.	2.6	\$ 650	\$ 1,690.00
Jess Commisso	02/06/20	Continue, from 2/5, to create assigned portion of illustrative structure deck based on Norton Rose sale computations of Mundipharma entities.	3.9	\$ 350	\$ 1,365.00
Devon Rowles	02/06/20	Revised structure deck with regards to Singapore asset/stock dispositions as well as the related tax consequences pursuant to consistency with other country structure decks	3.9	\$ 350	\$ 1,365.00
Madeleine Latham	02/06/20	Meeting with A. Desai (KPMG UK) to analyze and concurrently discuss the tax computations for the Purdue UK companies in scope. <u>Note</u> : two individuals performed this task with regards to the large volume of material to analyze.	3.9	\$ 380	\$ 1,482.00

EXHIBIT C1

Purdue Pharma, L.P.

Case No. 19-23649

Bankruptcy Tax Consulting Services
February 1, 2020 through February 29, 2020
(includes time not previously billed)

Name	Date	Description	Hours	Rate	Amount
Arpit Desai	02/06/20	Meeting with M. Latham (KPMG UK) to analyze and concurrently discuss the tax computations for the Purdue UK companies in scope. <u>Note</u> : two individuals performed this task with regards to the large volume of material to analyze.	3.9	\$ 750	\$ 2,925.00
Gavin Little	02/07/20	Perform Director review of list of key information obtained from tax computations as prepared by A. Desai and M. Latham (both KPMG UK).	0.5	\$ 985	\$ 492.50
Nick Morgan	02/07/20	0.3 Communication via email with KPMG project team regarding next steps related to Purdue structure deck updates with respect to the cash distribution analysis and timing on completion of deliverables; 0.4 Correspondence via email with NY KPMG International tax team with respect to their progress on structure deck updates.	0.7	\$ 350	\$ 245.00
Thomas Giordano	02/07/20	Continue, from 2/6/2020, to update the structure deck disposition scenarios for Mundipharma Deutschland based on feedback received.	0.7	\$ 350	\$ 245.00
Thomas Giordano	02/07/20	Revise the structure deck disposition scenarios for Napp Pharmaceutical Holdings Ltd. with respect to new client information received as of 2/7/20.	0.8	\$ 350	\$ 280.00
Nick Morgan	02/07/20	0.3 Communication via email with NY KPMG International tax team with respect to updates on the structure deck regarding tax consequences of assets sales and stock sales to UK entity 1; 0.3 Communication via email with NY KPMG International tax team with respect to updates on the UK entity structure deck regarding tax consequences of assets sales and stock sales to UK entity 2; 0.3 Computed tax consequences for specific UK entities for purposes of client deliverable	0.9	\$ 350	\$ 315.00
Dawn Krishnamurthy	02/07/20	Manager review of structure deck illustrating potential asset versus equity disposition scenarios for 3 United Kingdom entities as well as contribution of sales proceeds to a settlement vehicle, prepared by J. Commisso, D. Rowles, N. Morgan (all KPMG) for purpose of facilitating discussion of UK tax issues with UK member firm	0.9	\$ 695	\$ 625.50
Michael Land	02/07/20	Review of cash tax model with regards to inputs with focus on KPMG baseline inputs as well as how they may affect our model	1.4	\$ 534	\$ 747.60
Ashley Armfield	02/07/20	Senior Associate review of updates to cash tax model for payment of intercompany obligations / redemption of preferred stock that must occur after the sale of assets or simultaneous with equity sale.	1.7	\$ 534	\$ 907.80
Michael Land	02/07/20	Performed Senior Associate review of Purdue cash tax model with specific regards to US tax summary	1.9	\$ 534	\$ 1,014.60

EXHIBIT C1

Purdue Pharma, L.P.

Case No. 19-23649

Bankruptcy Tax Consulting Services

February 1, 2020 through February 29, 2020

(includes time not previously billed)

Name	Date	Description	Hours	Rate	Amount
Michael Land	02/07/20	Performed Senior Associate review of Purdue cash tax model with focus on sale analysis	1.9	\$ 534	\$ 1,014.60
Nick Morgan	02/07/20	Finalized version of UK entities in the structure deck (in preparation to send to the UK team) that includes updates related to the client deliverable slide deck.	2.0	\$ 350	\$ 700.00
Pete DiMatteo	02/07/20	Performed manager review and concurrently revised PowerPoint deck depicting proposed transactions relating to contemplated sale of specific UK subsidiary.	2.2	\$ 650	\$ 1,430.00
Thomas Giordano	02/07/20	Revised the structure deck disposition scenarios for Mundibiopharma Limited with respect to new client information received as of 2/7/20.	2.2	\$ 350	\$ 770.00
Ashley Armfield	02/07/20	Senior associate review of Napp Pharma (UK) structure deck as prepared by N. Morgan (KPMG).	2.4	\$ 534	\$ 1,281.60
Nick Morgan	02/07/20	1.6 Updates to the Purdue structure deck with respect to all UK entities regarding the presentation of cash movements from stock sales; 1.2 Revised the Purdue structure deck with respect all UK entities regarding the presentation of cash distributions on asset sales.	2.8	\$ 350	\$ 980.00
Thomas Giordano	02/07/20	Revised the structure deck disposition scenarios for Mundipharma Medical Company Limited with respect to new client information received as of 2/7/2020.	2.8	\$ 350	\$ 980.00
Devon Rowles	02/07/20	(3.2) Updated the structure decks related to Mundipharma DC BV (Netherlands) asset/stock dispositions including related tax consequences	3.2	\$ 350	\$ 1,120.00
Devon Rowles	02/07/20	(3.9) Updates to the structure decks related to Purdue Pharma Inc. (Canada) asset/stock dispositions including related tax consequences	3.9	\$ 350	\$ 1,365.00
Ashley Armfield	02/07/20	Review of cash tax model for shareholder level taxes / withholding implications pursuant to cash tax model; the purpose of this is to model out various potential dispositions of stock or equity interests of the mundipharma entities.	3.9	\$ 534	\$ 2,082.60
Devon Rowles	02/09/20	Updates to the master structure deck related to Canada, Netherlands, Singapore and Switzerland, for consistency purposes - pursuant to sending to all KPMG foreign member firms later this week.	1.1	\$ 350	\$ 385.00
Ashley Armfield	02/09/20	Performed Senior Associate review of master (i.e., combined version that combines all entities who have proposed dispositions) structure deck.	1.2	\$ 534	\$ 640.80
Nick Morgan	02/09/20	Performed structure deck updates to specific UK entities per direction from A. Armfield (KPMG)	2.0	\$ 350	\$ 700.00

EXHIBIT C1

Purdue Pharma, L.P.

Case No. 19-23649

Bankruptcy Tax Consulting Services

February 1, 2020 through February 29, 2020

(includes time not previously billed)

Name	Date	Description	Hours	Rate	Amount
Jess Commisso	02/10/20	Incorporated Brazil financial statement analysis (of tax attributes, reserves and audits) into a combined file of all Member Firm entities pursuant to Mundipharma entity analysis.	0.4	\$ 350	\$ 140.00
Pete DiMatteo	02/10/20	Call with C. Alonzo (KPMG Senior Associate International Tax) to discuss status of Purdue Pharma tax project and next steps as of 2/10/2020.	0.5	\$ 650	\$ 325.00
Courtney Alonzo	02/10/20	Call with P. DiMatteo (KPMG Manager of International Tax) to discuss status of Purdue Pharma tax project and next steps as of 2/10/2020.	0.5	\$ 534	\$ 267.00
Casey Nunez	02/10/20	Senior manager review of summary detailing new Purdue Pharma documentation uploaded to data room as of 2/10/2020.	0.7	\$ 744	\$ 520.80
Thomas Giordano	02/10/20	Drafted US tax consequences / considerations related to the various steps in the structure deck disposition scenarios for Mundipharma Medical Company	0.9	\$ 350	\$ 315.00
Thomas Giordano	02/10/20	Revised the structure deck disposition scenarios to include updates related to Mundipharma Deutschland as of 2/10/20.	0.9	\$ 350	\$ 315.00
Thomas Giordano	02/10/20	Drafted US tax consequences / considerations related to the various steps in the structure deck disposition scenarios for Napp Pharmaceutical Holdings Limited	1.1	\$ 350	\$ 385.00
Devon Rowles	02/10/20	Review of Purdue Pharma court docket to identify new data relevant to tax analysis as of 2/10/2020.	1.1	\$ 350	\$ 385.00
Devon Rowles	02/10/20	Updating the glossary for entity names/terms in the UK structure deck related to asset/stock disposition	1.1	\$ 350	\$ 385.00
Devon Rowles	02/10/20	Updating the master glossary/legend for the master structure deck regarding asset/stock disposition as well as related tax consequences	1.1	\$ 350	\$ 385.00
Thomas Giordano	02/10/20	Continue, from earlier in the day, to draft US tax consequences, as well as related considerations, related to the various steps in the structure deck disposition scenarios for Mundipharma Deutschland	1.2	\$ 350	\$ 420.00
Dawn Krishnamurthy	02/10/20	1.2 (Continued from Friday 2/7) to perform Manager review of structure deck illustrating potential asset versus equity disposition scenarios for a UK disposition entity, prepared by J. Commisso, D. Rowles, N. Morgan (all KPMG) for purpose of illustrating disposition steps for asset versus equity disposition, post sale restructuring and contribution of sales proceeds to settlement vehicle; (0.1) manager review of list of updates to the Norton Rose data room (prepared by J. Commisso-KPMG) and concurrently cross check information received to confirm responsiveness to KPMG requests.	1.3	\$ 695	\$ 903.50

EXHIBIT C1

Purdue Pharma, L.P.

Case No. 19-23649

Bankruptcy Tax Consulting Services
February 1, 2020 through February 29, 2020
(includes time not previously billed)

Name	Date	Description	Hours	Rate	Amount
Jess Commisso	02/10/20	Created excel tables displaying intercompany loans / preferred equity redemptions between Mundipharma independent associated companies to provide support for cash flows displayed in structure deck.	1.7	\$ 350	\$ 595.00
Henrique Palm	02/10/20	Managing Director level review (from a Brazilian tax perspective) of the financial documentation provided.	2.0	\$ 985	\$ 1,970.00
Ashley Armfield	02/10/20	Senior Associate review of structure deck to sent to UK team for comments for Mundipharma Medical Company Limited.	2.3	\$ 534	\$ 1,228.20
Nick Morgan	02/10/20	2.5 Completed the third UK (entity 3) organizational chart structuring for client deliverable.	2.5	\$ 350	\$ 875.00
Ashley Armfield	02/10/20	Senior Associate review of structure deck to send to UK team for comments for Napp Holdings.	2.6	\$ 534	\$ 1,388.40
Isaac Hirsch	02/10/20	Performed Managing Director review of latest updates to Purdue cash tax cost model (prepared by A. Armfield - KPMG) to confirm incorporation of review comments (from self).	2.9	\$ 819	\$ 2,375.10
Ashley Armfield	02/10/20	Senior Associate review of structure deck to send to UK team for comments for Mundibiopharma Limited.	3.1	\$ 534	\$ 1,655.40
Nick Morgan	02/10/20	1.0 Completed the first UK (entity 1) organizational chart structuring for client deliverable; 2.5 Completed the second UK (entity 2) organizational chart structuring for client deliverable in preparation to sent to KPMG UK project team.	3.5	\$ 350	\$ 1,225.00
Jess Commisso	02/10/20	Created assigned portion of illustrative structure deck, as of 2/10/2020, based on Norton Rose sale computations of Mundipharma entities pursuant to sharing with our member firms for sale / tax analysis purposes.	3.9	\$ 350	\$ 1,365.00
Thomas Giordano	02/10/20	Drafted US tax consequences, as well as related considerations, related to the various steps in the structure deck disposition scenarios for Mundipharma Deutschland	3.9	\$ 350	\$ 1,365.00
Devon Rowles	02/10/20	Revised the UK structure deck related to asset/stock dispositions including related tax consequences per review comments received from senior associate as of 2/10.	3.9	\$ 350	\$ 1,365.00
Devon Rowles	02/11/20	Drafted email to KPMG Netherlands regarding additional Netherlands tax returns received to facilitate timely/efficient review.	0.2	\$ 350	\$ 70.00
Michael Land	02/11/20	Review of data room documentation related to UK annual compliance reports to gain insight into tax profile.	0.4	\$ 534	\$ 213.60
Denis Larkin	02/11/20	Performed Principal review and concurrently update email drafted by H. Lewis (KPMG Australia) summarizing Australian tax findings prior to sending to KPMG US for review.	0.6	\$ 566	\$ 339.60

EXHIBIT C1

Purdue Pharma, L.P.

Case No. 19-23649

Bankruptcy Tax Consulting Services
February 1, 2020 through February 29, 2020
(includes time not previously billed)

Name	Date	Description	Hours	Rate	Amount
Devon Rowles	02/11/20	(.7) Updated the information request list to include additional tax documents received in the virtual data room as of 2/11/20.	0.7	\$ 350	\$ 245.00
Thomas Giordano	02/11/20	Drafted US tax consequences / considerations related to the various steps in the structure deck disposition scenarios for Mundibiopharma Limited	0.7	\$ 350	\$ 245.00
Dawn Krishnamurthy	02/11/20	Continued (from 2/10) to perform Manager review of updated information tracker prepared by D. Rowles (KPMG), while concurrently cross-checking 2016 & 2017 compliance reports for 2 UK entities (0.1), 2017 tax returns for 7 Mundipharma entities in the Netherlands (0.3), 2017 & 2018 notifications for 12 UK entities for the purpose of determining responsiveness to KPMG requests (0.4).	0.8	\$ 695	\$ 556.00
Jess Commisso	02/11/20	Compiled new provided by client documentation, including tax returns / diverted profits tax information, found in the virtual data room in preparation to provide to our UK member firm pursuant to tax analysis.	0.8	\$ 350	\$ 280.00
Denis Larkin	02/11/20	Discussion with H. Lewis, D. Larkin and J. Davis (all KPMG) Australia) in respect to discuss findings related to review of Mundipharma Pty Limited financial statements and tax returns for 2017 and 2018 years.	0.9	\$ 566	\$ 509.40
Hanah Lewis	02/11/20	Discussion with H. Lewis, D. Larkin and J. Davis (all KPMG) Australia) in respect to discuss findings related to review of Mundipharma Pty Limited financial statements and tax returns for 2017 and 2018 years.	0.9	\$ 239	\$ 215.10
Justin Davis	02/11/20	Discussion with H. Lewis, D. Larkin and J. Davis (all KPMG) Australia) in respect to discuss findings related to review of Mundipharma Pty Limited financial statements and tax returns for 2017 and 2018 years.	0.9	\$ 655	\$ 589.50
Thomas Giordano	02/11/20	Drafted US tax consequences / considerations related to the various steps in the structure deck disposition scenarios for Mundipharma Medical Company Limited	0.9	\$ 350	\$ 315.00
Ashley Armfield	02/11/20	Meeting with A. Armfield and J. Commisso (both KPMG) regarding the set-up of cash tax model pursuant to performing appropriate updates with regards to Director review comments.	0.9	\$ 534	\$ 480.60
Jess Commisso	02/11/20	Meeting with A. Armfield and J. Commisso (both KPMG) regarding the set-up of cash tax model pursuant to performing appropriate updates with regards to Director review comments.	0.9	\$ 350	\$ 315.00
Michael Land	02/11/20	Review of data room documentation related to Netherlands tax returns to gain insight into tax profile.	0.9	\$ 534	\$ 480.60

EXHIBIT C1

Purdue Pharma, L.P.

Case No. 19-23649

Bankruptcy Tax Consulting Services
February 1, 2020 through February 29, 2020
(includes time not previously billed)

Name	Date	Description	Hours	Rate	Amount
Denis Larkin	02/11/20	Review of additional provided by client documentation in the Purdue Data Room as of 2/11/2020 to identify relevant documents to be utilized in tax analysis.	1.0	\$ 566	\$ 566.00
Howard Steinberg	02/11/20	Partner review of data room updates based on information provided, specifically to gain insight into tax returns / financial statements received to date.	1.0	\$ 856	\$ 856.00
Dawn Krishnamurthy	02/11/20	(1.1) Manager review of UK Mundipharma Disposition Analysis - as prepared by J. Commisso, D. Rowles, N. Morgan (KPMG), specifically a portion of the global structure deck, and concurrently draft review comments related to same.	1.1	\$ 695	\$ 764.50
Hanah Lewis	02/11/20	Drafting email to the US project team summarizing the outcome of the Australian review.	1.1	\$ 239	\$ 262.90
Michael Land	02/11/20	Review of data room documentation related to UK 2017 diverted profits tax to gain insight into tax profile.	1.2	\$ 534	\$ 640.80
Pete DiMatteo	02/11/20	Updated outline regarding permissibility of certain potential tax deductions	1.2	\$ 650	\$ 780.00
Devon Rowles	02/11/20	(1.4) Updating the virtual data room tracker to include new provided by client document received as of 2/11/2020 that includes exact file name / location in the data room to facilitate project team review.	1.4	\$ 350	\$ 490.00
Devon Rowles	02/11/20	(1.7) Aggregated new documentation in the share site as of 2/11/2020 into each relevant country/entity folder to facilitate member firms tax analysis of same.	1.7	\$ 350	\$ 595.00
Hanah Lewis	02/11/20	Performed initial review of documentation in the Purdue Data Room as of 2/11/2020 (including the Mundipharma Pty Limited financial statements from 2016, 2017 and 2018 financial years, as well as tax returns relating to the 2017 and 2018 years).	2.1	\$ 239	\$ 501.90
Jess Commisso	02/11/20	Performed research related to the tax implications incorporated into the cash tax model pursuant to the ability to perform updates to the model.	2.4	\$ 350	\$ 840.00
Ashley Armfield	02/11/20	Performed research of various types of trusts under subchapter J of the internal revenue code to gain insight into the entity level versus flow through properties associates with various trusts (which impacts the analysis with regards to whether there will be additional tax at the trust level and ultimately impacts the net proceeds available to be contributed to the settlement vehicle).	2.8	\$ 534	\$ 1,495.20
Thomas Giordano	02/11/20	Drafted the US tax consequences / considerations related to the various steps in the structure deck disposition scenarios for Napp Pharmaceutical Holdings Ltd.	3.2	\$ 350	\$ 1,120.00

EXHIBIT C1

Purdue Pharma, L.P.

Case No. 19-23649

Bankruptcy Tax Consulting Services
February 1, 2020 through February 29, 2020
(includes time not previously billed)

Name	Date	Description	Hours	Rate	Amount
Thomas Giordano	02/11/20	Drafted US tax consequences / considerations related to the various steps in the structure deck disposition scenarios for Mundipharma Deutschland	3.4	\$ 350	\$ 1,190.00
Jess Commisso	02/11/20	Updates to the cash tax model based on Director review comments received as of 2/11/2020.	3.9	\$ 350	\$ 1,365.00
Thomas Giordano	02/12/20	Review and concurrently revise draft US tax consequences and considerations related to the various steps in the structure deck disposition scenarios for Mundipharma Deutschland	0.3	\$ 350	\$ 105.00
Thomas Giordano	02/12/20	Review and concurrently revised draft US tax consequences and considerations related to the various steps in the structure deck disposition scenarios for Mundipharma Medical Company Limited	0.3	\$ 350	\$ 105.00
Thomas Giordano	02/12/20	Reviewed and concurrently revised draft US tax consequences and considerations related to the various steps in the structure deck disposition scenarios for Napp Pharmaceutical Holdings Ltd.	0.3	\$ 350	\$ 105.00
Casey Nunez	02/12/20	Preparation for call regarding Mundipharma ownership trust tax diligence by reviewing relevant documentation previously provided by Norton Rose.	0.6	\$ 744	\$ 446.40
Tracy Stone	02/12/20	Consideration of questions related to trusts in preparation or upcoming call with KPMG M&A, Nation Tax Trusts and KPMG International Tax (on same day).	1.0	\$ 906	\$ 906.00
Nick Morgan	02/12/20	1.1 Review of additional updates from team members regarding structuring / modeling components of various entities for Purdue organizational chart (including related tax consequences) with focus on new tasks required for client deliverable.	1.1	\$ 350	\$ 385.00
Devon Rowles	02/12/20	Continued, same day, to revise the 126 page master structure deck with regards to updates related to asset/stock dispositions (including related tax consequences) per review comments from senior associate.	1.1	\$ 350	\$ 385.00
Thomas Giordano	02/12/20	Revised outline of research an analysis regarding certain potential tax deductions in preparation for presentation to P. DiMatteo and I. Hirsch (both KPMG)	1.7	\$ 350	\$ 595.00
Dawn Krishnamurthy	02/12/20	Performed analysis relating to tax deductibility of certain potential contributions.	2.4	\$ 695	\$ 1,668.00
Jess Commisso	02/12/20	Performed research regarding certain tax issues fro incorporation into the cash tax model pursuant to the ability to perform updates to the model.	2.4	\$ 350	\$ 840.00

EXHIBIT C1

Purdue Pharma, L.P.

Case No. 19-23649

Bankruptcy Tax Consulting Services

February 1, 2020 through February 29, 2020

(includes time not previously billed)

Name	Date	Description	Hours	Rate	Amount
Michael Land	02/12/20	Review of Prime Clerk document notice of proposed order / notice of filing of proposed sixth amended preliminary injunction order for purposes of identifying any changes to the debtor or plaintiff parties	2.6	\$ 534	\$ 1,388.40
Thomas Giordano	02/12/20	Updated draft US tax consequences / considerations related to the various steps in the structure deck disposition scenarios for Mundibipharma Limited for S Corp scenarios.	2.8	\$ 350	\$ 980.00
Jess Commisso	02/12/20	Revised the Purdue cash tax model based on review comments received from I. Hirsch (KPMG Managing Director) as of 2/12/2020.	3.4	\$ 350	\$ 1,190.00
Devon Rowles	02/12/20	Began to revise the 126 page master structure deck with regards to updates related to asset/stock dispositions (including related tax consequences) per review comments from senior associate.	3.9	\$ 350	\$ 1,365.00
Devon Rowles	02/12/20	Continue, from same day, to revise the 126 page master structure deck with regards to updates related to asset/stock dispositions (including related tax consequences) per review comments from senior associate.	3.9	\$ 350	\$ 1,365.00
Dawn Krishnamurthy	02/13/20	(0.1) Review of Norton Rose organizational charts for trust structure and drafted email to C. Nunez (KPMG) regarding same; (0.1) Review of newly provided information in Norton Rose data room as of 2/13 for purpose of determining responsiveness to KPMG tax documentation requests.	0.2	\$ 695	\$ 139.00
Courtney Alonzo	02/13/20	Performed research related certain potential tax deductions contributing with regards to Purdue tax matter.	0.5	\$ 534	\$ 267.00
Howard Steinberg	02/13/20	Call with M. Hoffenberg, T. Stone, P. Kunkel and H. Steinberg (all KPMG) to discuss questions to be addressed during upcoming call with Norton Rose related to trust structure.	0.7	\$ 856	\$ 599.20
Mark Hoffenberg	02/13/20	Call with M. Hoffenberg, T. Stone, P. Kunkel and H. Steinberg (all KPMG) to discuss questions to be addressed during upcoming call with Norton Rose related to trust structure.	0.7	\$ 980	\$ 686.00
Paul Kunkel	02/13/20	Call with M. Hoffenberg, T. Stone, P. Kunkel and H. Steinberg (all KPMG) to discuss questions to be addressed during upcoming call with Norton Rose related to trust structure.	0.7	\$ 744	\$ 520.80
Tracy Stone	02/13/20	Call with M. Hoffenberg, T. Stone, P. Kunkel and H. Steinberg (all KPMG) to discuss questions to be addressed during upcoming call with Norton Rose related to trust structure.	0.7	\$ 906	\$ 634.20
Michael Land	02/13/20	Perform senior associate review of Singapore disposition scenarios related to asset versus stock sale	0.7	\$ 534	\$ 373.80

EXHIBIT C1

Purdue Pharma, L.P.

Case No. 19-23649

Bankruptcy Tax Consulting Services
February 1, 2020 through February 29, 2020
(includes time not previously billed)

Name	Date	Description	Hours	Rate	Amount
Devon Rowles	02/13/20	Reviewed Purdue court docket as of 2/23/2020 to locate relevant tax documentation including tax attributes, tax exposures, basis, etc.	0.8	\$ 350	\$ 280.00
Michael Land	02/13/20	Performed Senior Associate review of Netherlands disposition scenarios related to asset versus stock sale	0.9	\$ 534	\$ 480.60
Ashley Armfield	02/13/20	Review questions posed by J. Commisso (KPMG) related to the Purdue cash tax model and concurrently research (as needed) information in order to respond - pursuant to preparing the cash tax model.	1.0	\$ 534	\$ 534.00
Michael Land	02/13/20	Perform senior associate review of Germany disposition scenarios related to asset versus stock sale	1.1	\$ 534	\$ 587.40
Michael Land	02/13/20	Performed senior associate review of Canada disposition scenarios related to asset versus stock sale	1.1	\$ 534	\$ 587.40
Michael Land	02/13/20	Performed senior associate review of Switzerland disposition scenarios related to asset versus stock sale	1.1	\$ 534	\$ 587.40
Pete DiMatteo	02/13/20	Review of Purdue structure to determine ownership of various Mundipharma entities for purposes of US tax analyses.	1.1	\$ 650	\$ 715.00
Casey Nunez	02/13/20	Meeting with Norton Rose, Akin Gump, and Davis Polk, M. Hoffenberg, H. Steinberg, I. Hirsch, P. Kunkel and C. Nunez (KPMG) regarding the Mortimer and Raymond trust ownership for purposes of understanding potential tax issues upon distributions to or from the trusts.	1.2	\$ 744	\$ 892.80
Howard Steinberg	02/13/20	Meeting with Norton Rose, Akin Gump, and Davis Polk, M. Hoffenberg, H. Steinberg, I. Hirsch, P. Kunkel and C. Nunez (KPMG) regarding the Mortimer and Raymond trust ownership for purposes of understanding potential tax issues upon distributions to or from the trusts.	1.2	\$ 856	\$ 1,027.20
Isaac Hirsch	02/13/20	Meeting with Norton Rose, Akin Gump, and Davis Polk, M. Hoffenberg, H. Steinberg, I. Hirsch, P. Kunkel and C. Nunez (KPMG) regarding the Mortimer and Raymond trust ownership for purposes of understanding potential tax issues upon distributions to or from the trusts.	1.2	\$ 819	\$ 982.80
Tracy Stone	02/13/20	Meeting with Norton Rose, Akin Gump, and Davis Polk, M. Hoffenberg, H. Steinberg, I. Hirsch, P. Kunkel and C. Nunez (KPMG) regarding the Mortimer and Raymond trust ownership for purposes of understanding potential tax issues upon distributions to or from the trusts.	1.2	\$ 906	\$ 1,087.20
Mark Hoffenberg	02/13/20	Meeting with Norton Rose, Akin Gump, and Davis Polk, M. Hoffenberg, H. Steinberg, I. Hirsch, P. Kunkel and C. Nunez (KPMG) regarding the Mortimer and Raymond trust ownership for purposes of understanding potential tax issues upon distributions to or from the trusts.	1.2	\$ 980	\$ 1,176.00

EXHIBIT C1

Purdue Pharma, L.P.

Case No. 19-23649

Bankruptcy Tax Consulting Services
February 1, 2020 through February 29, 2020
(includes time not previously billed)

Name	Date	Description	Hours	Rate	Amount
Paul Kunkel	02/13/20	Meeting with Norton Rose, Akin Gump, and Davis Polk, M. Hoffenberg, H. Steinberg, I. Hirsch, P. Kunkel and C. Nunez (KPMG) regarding the Mortimer and Raymond trust ownership for purposes of understanding potential tax issues upon distributions to or from the trusts.	1.2	\$ 744	\$ 892.80
Jess Commisso	02/13/20	Performed research related to the tax implications incorporated into the most recent version of the Purdue cash tax model pursuant to the ability to perform additional updates to the model.	1.3	\$ 350	\$ 455.00
Michael Land	02/13/20	Performed senior associate review of UK disposition scenarios related to asset versus stock sale	1.3	\$ 534	\$ 694.20
Tracy Stone	02/13/20	Perform Principal WNT review of Purdue term sheet in conjunction with organizational chart to consider trust issues in preparation for upcoming trust call (.8); consider rationale for accessing proceeds from sale of Mundipharma entities owned by trusts (0.6) and draft email to project team re same (.1)	1.5	\$ 906	\$ 1,359.00
Zafer Ülgen	02/13/20	Prepare draft e-mail detailing key findings/observations with respect to the 2017 Dutch CIT returns of some of Ladenburg BV, Mundipharma Bradenton BV, Accardi BV, Vaccaro BV, Tacca BV and Tenna BV (1.4); draft email to send the draft e-mail to A. Rambhadrachari (Partner KPMG Netherlands) for review (0.1).	1.5	\$ 380	\$ 570.00
Isaac Hirsch	02/13/20	Review summary of E&Y Project Malta report for background necessary to prepare the cash tax model	1.6	\$ 819	\$ 1,310.40
Thomas Giordano	02/13/20	Updated outline of certain potential tax deduction research & analysis in preparation for presentation to I. Hirsch (KPMG Managing Director).	2.0	\$ 350	\$ 700.00
Jess Commisso	02/13/20	Incorporating updates requested by I. Hirsch (KPMG Managing Director) to the cash tax model as of 2/13/20.	2.8	\$ 350	\$ 980.00
Devon Rowles	02/13/20	Continued, from earlier in the day, to revise the 126 page master structure deck with regards to updates related to asset/stock dispositions (including related tax consequences) per review comments from senior associate.	3.9	\$ 350	\$ 1,365.00
Ashley Armfield	02/13/20	Review of director commentary (relating to foreign tax credits, and Canada updates) for cash tax model updates on 2/13/2020.	0.2	\$ 534	\$ 106.80
Ashley Armfield	02/13/20	Performed Senior Associate review of updates made to Purdue cash tax model (by J. Commisso, KPMG, per director commentary received as of 2/13/2020) while concurrently updating, as necessary.	1.6	\$ 534	\$ 854.40

EXHIBIT C1

Purdue Pharma, L.P.

Case No. 19-23649

Bankruptcy Tax Consulting Services
February 1, 2020 through February 29, 2020
(includes time not previously billed)

Name	Date	Description	Hours	Rate	Amount
Ashley Armfield	02/13/20	Meeting with A. Armfield (KPMG) and J. Commisso (KPMG) to discuss model updates as - per director commentary received as of 2/13/2020.	2.1	\$ 534	\$ 1,121.40
Jess Commisso	02/13/20	Meeting with A. Armfield (KPMG) and J. Commisso (KPMG) to discuss model updates as - per director commentary received as of 2/13/2020.	2.1	\$ 350	\$ 735.00
Jess Commisso	02/13/20	Executing Purdue cash tax model updates based on director comments received as of 2/13/2020.	1.8	\$ 350	\$ 630.00
Zafer Ülgen	02/13/20	Upon request of D. Rowles (KPMG United States), reviewed information included in share file on Dutch Purdue companies (2017 Dutch CIT returns of Ladenburg BV, Mundipharma Bradenton BV, Accardi BV, Vaccaro BV, Tacca BV and Tenna BV) to identify key findings available at the level of the Dutch Purdue companies.	4.0	\$ 380	\$ 1,520.00
Dawn Krishnamurthy	02/14/20	(0.1) Review of documentation available in Norton Rose data room as of 2/14, with regards to KPMG information requests; (0.5) Review of notes from discussion of trust related issues (with J. Robbins from Norton Rose) as prepared by M. Land (KPMG) for purpose of gaining insight regarding status of analysis of deductibility of settlement payments as well as flow of funds through trust structure; (0.1) drafted follow-up email to C. Nunez (KPMG) regarding next steps related to trust information requests.	0.7	\$ 695	\$ 486.50
Dawn Krishnamurthy	02/14/20	Perform Manager review of trust related information requests and concurrently compare to information discussed during discussion of trust issues on 2/13 per M. Land (KPMG) notes (0.4); Draft email to C. Nunez and H. Steinberg (both KPMG) with draft trust information request language (0.3)	0.7	\$ 695	\$ 486.50
Devon Rowles	02/14/20	Discussion with D. Rowles and J. Commisso (KPMG) regarding structure deck updates due to receipt of new trust information and senior review commentary.	0.8	\$ 350	\$ 280.00
Jess Commisso	02/14/20	Discussion with D. Rowles and J. Commisso (KPMG) regarding structure deck updates due to receipt of new trust information and senior review commentary.	0.8	\$ 350	\$ 280.00
Ashley Armfield	02/14/20	Meeting with A. Armfield and J. Commisso (both KPMG) for a working group session discussing modeling considerations with respect to preferred shareholders (i.e., the treatment when the shareholder is PRA LP or not).	0.8	\$ 534	\$ 427.20
Jess Commisso	02/14/20	Meeting with A. Armfield and J. Commisso (both KPMG) for a working group session discussing modeling considerations with respect to preferred shareholders (i.e., the treatment when the shareholder is PRA LP or not).	0.8	\$ 350	\$ 280.00

EXHIBIT C1

Purdue Pharma, L.P.

Case No. 19-23649

Bankruptcy Tax Consulting Services

February 1, 2020 through February 29, 2020

(includes time not previously billed)

Name	Date	Description	Hours	Rate	Amount
Courtney Alonzo	02/14/20	(1.0) Performed background research regarding certain tax issues with respect to flow-through entities with regards to applicability to Purdue matter.	1.0	\$ 534	\$ 534.00
Isaac Hirsch	02/14/20	Managing Director review of updates to the trade or business analysis prepared by P. DiMatteo KPMG) for purposes of analyzing tax treatment of settlement payments	1.1	\$ 819	\$ 900.90
Michael Land	02/14/20	Performed research regarding trust distributions.	1.1	\$ 534	\$ 587.40
Pete DiMatteo	02/14/20	Review and concurrently update PowerPoint presentation depicting proposed transactions for a UK subsidiary, including anticipated US tax consequences.	1.2	\$ 650	\$ 780.00
Thomas Giordano	02/14/20	Continue, from 2/10/2020, to revise draft US tax consequences / considerations based on further analysis of relevant rules related to the various steps in the structure deck disposition scenarios for Mundipharma Deutschland	1.3	\$ 350	\$ 455.00
Ashley Armfield	02/14/20	Meeting with A. Armfield, M. Land, D. Rowles (KPMG) to discuss changes to the structure deck re Mundipharma Singapore Holdings Pte. Limited asset/stock dispositions and related tax consequences	1.3	\$ 534	\$ 694.20
Devon Rowles	02/14/20	Meeting with A. Armfield, M. Land, D. Rowles (KPMG) to discuss changes to the structure deck re Mundipharma Singapore Holdings Pte. Limited asset/stock dispositions and related tax consequences	1.3	\$ 350	\$ 455.00
Michael Land	02/14/20	Meeting with A. Armfield, M. Land, D. Rowles (KPMG) to discuss changes to the structure deck re Mundipharma Singapore Holdings Pte. Limited asset/stock dispositions and related tax consequences	1.3	\$ 534	\$ 694.20
Ashley Armfield	02/14/20	Meeting with D. Rowles, M. Land, and A. Armfield (All KPMG) to review changes to the structure deck re Purdue Pharma Inc. (Canada) asset/stock dispositions and related tax consequences	1.3	\$ 534	\$ 694.20
Devon Rowles	02/14/20	Meeting with D. Rowles, M. Land, and A. Armfield (All KPMG) to review changes to the structure deck re Purdue Pharma Inc. (Canada) asset/stock dispositions and related tax consequences	1.3	\$ 350	\$ 455.00
Michael Land	02/14/20	Meeting with D. Rowles, M. Land, and A. Armfield (All KPMG) to review changes to the structure deck re Purdue Pharma Inc. (Canada) asset/stock dispositions and related tax consequences	1.3	\$ 534	\$ 694.20
Ashley Armfield	02/14/20	Meeting with M. Land, A. Armfield, D. Rowles (KPMG) to review and concurrently discuss changes to the structure deck re Mundibipharma Limited (United Kingdom) asset/stock dispositions and related tax consequences	1.3	\$ 534	\$ 694.20

EXHIBIT C1

Purdue Pharma, L.P.

Case No. 19-23649

Bankruptcy Tax Consulting Services
February 1, 2020 through February 29, 2020
(includes time not previously billed)

Name	Date	Description	Hours	Rate	Amount
Devon Rowles	02/14/20	Meeting with M. Land, A. Armfield, D. Rowles (KPMG) to review and concurrently discuss changes to the structure deck re Mundibiopharma Limited (United Kingdom) asset/stock dispositions and related tax consequences	1.3	\$ 350	\$ 455.00
Michael Land	02/14/20	Meeting with M. Land, A. Armfield, D. Rowles (KPMG) to review and concurrently discuss changes to the structure deck re Mundibiopharma Limited (United Kingdom) asset/stock dispositions and related tax consequences	1.3	\$ 534	\$ 694.20
Pete DiMatteo	02/14/20	Review and concurrently update PowerPoint presentation depicting proposed transactions for a German subsidiary, including anticipated US tax consequences.	1.5	\$ 650	\$ 975.00
Nick Morgan	02/14/20	1.7: Analyzed US organizational chart to gain insight regarding potential tax consequences upon distribution of cash proceeds to the settlement vehicle.	1.7	\$ 350	\$ 595.00
Pete DiMatteo	02/14/20	Performed international tax manager review and concurrently update PowerPoint presentation depicting proposed transactions for Mundibiopharma Limited, including anticipated US tax consequences.	1.8	\$ 650	\$ 1,170.00
Ashley Armfield	02/14/20	Senior Associate review of summary of tax attributes as provided by J. Commisso (KPMG) pursuant to validating other information relating to the Mundipharma and Purdue entities (e.g., outstanding cash on hand, intercompany receivables, preferred equity).	1.9	\$ 534	\$ 1,014.60
Thomas Giordano	02/14/20	Continue, from 2/12/2020, to revise draft US tax consequences / considerations based on further analysis of relevant rules related to the various steps in the structure deck disposition scenarios for Mundipharma Medical Company Limited	2.3	\$ 350	\$ 805.00
Nick Morgan	02/14/20	2.0 Created the upper tier portion of the US organizational chart in PowerPoint for visualization in the structure deck deliverable; 0.6 Review the Norton Rose report of trust issues with focus on potential tax consequences and concurrently drafted notes to share with project team regarding potential issues identified.	2.6	\$ 350	\$ 910.00
Thomas Giordano	02/14/20	Continue, from 2/12/2020, to revise draft US tax consequences and considerations based on further analysis of relevant rules related to the various steps in the structure deck disposition scenarios for Napp Pharmaceutical Holdings Ltd.	2.9	\$ 350	\$ 1,015.00
Jess Commisso	02/14/20	Continued, same day, to update the Purdue cash tax model as requested by I. Hirsch (KPMG Managing Director) as of 2/14/20.	3.3	\$ 350	\$ 1,155.00

EXHIBIT C1

Purdue Pharma, L.P.

Case No. 19-23649

Bankruptcy Tax Consulting Services
February 1, 2020 through February 29, 2020
(includes time not previously billed)

Name	Date	Description	Hours	Rate	Amount
Devon Rowles	02/14/20	Continued, from 2/13, to revise the 126 page master structure deck with regards to updates related to asset/stock dispositions (including related tax consequences) per review comments from senior associate.	3.9	\$ 350	\$ 1,365.00
Jess Commisso	02/14/20	Updated the Purdue cash tax model as requested by I. Hirsch (KPMG Managing Director) as of 2/14/20.	3.9	\$ 350	\$ 1,365.00
Frank Caratzola	02/14/20	3.0 Performed research regarding certain tax credits related to client structure; 2.0 Performed research regarding residency/sourcing rules as related to trusts and the beneficiaries of such trusts.	5.0	\$ 534	\$ 2,670.00
Dawn Krishnamurthy	02/16/20	Manager review of listing of tax residency of trust beneficiaries prepared by B. Davies (KPMG paraprofessional) and D. Rowles (KPMG) for purpose of gaining insight regarding applicable taxing jurisdiction as part of analysis of trust issues and concurrently draft review comments related to same.	0.3	\$ 695	\$ 208.50
Isaac Hirsch	02/16/20	Analyzed outline regarding tax treatment of settlement proceeds for purposes of incorporation into the analysis in the cash tax model	1.3	\$ 819	\$ 1,064.70
Devon Rowles	02/16/20	Creating the Sackler Family tree to gain insight related to the US and non-US family as well as confirming which family is the beneficiary of each trust	2.2	\$ 350	\$ 770.00
Devon Rowles	02/17/20	Communication with KPMG Germany regarding additional provided by client data in the data room as of 2/17/2020 to facilitate timely and efficient review of same.	0.2	\$ 350	\$ 70.00
Devon Rowles	02/17/20	Draft email to KPMG Switzerland regarding new tax return documentation available as of 2/17 - to facilitate timely and efficient review.	0.2	\$ 350	\$ 70.00
Devon Rowles	02/17/20	Updated the preliminary analysis sale computations provided by Norton Rose for the exhibit listing for KPMG US cash tax model	0.4	\$ 350	\$ 140.00
Dawn Krishnamurthy	02/17/20	Manager review of information tracker prepared by J. Commisso (KPMG) and concurrently cross check German and Swiss tax returns for purposes of determining responsiveness to KPMG requests (0.4); draft email to J. Commisso (KPMG) regarding same with comments on Transfer Pricing documentation received (0.2).	0.6	\$ 695	\$ 417.00
Thomas Giordano	02/17/20	Conducted research on various trust / estate planning issues in preparation for Purdue scenario planning.	0.7	\$ 350	\$ 245.00
Pete DiMatteo	02/17/20	Discussion with P. DiMatteo (KPMG) and T. Giordano (KPMG) regarding additional revisions be performed to the Purdue structure deck disposition scenarios for a specific German subsidiary.	0.8	\$ 650	\$ 520.00

EXHIBIT C1

Purdue Pharma, L.P.

Case No. 19-23649

Bankruptcy Tax Consulting Services

February 1, 2020 through February 29, 2020

(includes time not previously billed)

Name	Date	Description	Hours	Rate	Amount
Thomas Giordano	02/17/20	Discussion with P. DiMatteo (KPMG) and T. Giordano (KPMG) regarding additional revisions be performed to the Purdue structure deck disposition scenarios for a specific German subsidiary.	0.8	\$ 350	\$ 280.00
Devon Rowles	02/17/20	Updated the member firm information tracker document to include key findings of KPMG Switzerland related to tax reserves / tax audits	0.8	\$ 350	\$ 280.00
Devon Rowles	02/17/20	Updating the member firm information tracker document to include key findings of KPMG Australia related to tax reserves / tax audits	0.8	\$ 350	\$ 280.00
Howard Steinberg	02/17/20	Partner review of information tracker provided by D. Krishnamurthy (KPMG) relating to updated tax return filings and transfer pricing documentation available.	1.0	\$ 856	\$ 856.00
Jess Commisso	02/17/20	Updated the Purdue cash tax model as requested by I. Hirsch (KPMG Managing Director) as of 2/17/20.	1.2	\$ 350	\$ 420.00
Ashley Armfield	02/17/20	Meeting with I. Hirsch and A. Armfield (both KPMG) to discuss implications of trust call (i.e., which entities will be contributing funds to the settlement vehicle) from prior week and how to implement into the cash tax model.	1.4	\$ 534	\$ 747.60
Isaac Hirsch	02/17/20	Meeting with I. Hirsch and A. Armfield (both KPMG) to discuss implications of trust call (i.e., which entities will be contributing funds to the settlement vehicle) from prior week and how to implement into the cash tax model.	1.4	\$ 819	\$ 1,146.60
Arpit Desai	02/17/20	Meeting with P. Harden G. Little, and A Desai (KPMG UK).to review and concurrently discuss structure of Purdue Pharma L.P. including initial trust tax implications -based on the information provided to date.	1.5	\$ 750	\$ 1,125.00
Gavin Little	02/17/20	Meeting with P. Harden G. Little, and A Desai (KPMG UK).to review and concurrently discuss structure of Purdue Pharma L.P. including initial trust tax implications -based on the information provided to date.	1.5	\$ 985	\$ 1,477.50
Paul Harden	02/17/20	Meeting with P. Harden G. Little, and A Desai (KPMG UK).to review and concurrently discuss structure of Purdue Pharma L.P. including initial trust tax implications -based on the information provided to date.	1.5	\$ 985	\$ 1,477.50
Jess Commisso	02/17/20	Concurrently updated the information request list and virtual data room tracker based on new documentation provided by client as of 2/17/20 - pursuant to communicating updates/ outstanding items to project team.	1.6	\$ 350	\$ 560.00
Madeleine Latham	02/17/20	Reviewed various Purdue Pharma L.P. structures, identifying the different trust ownership structures based on the information provided to date.	2.0	\$ 380	\$ 760.00

EXHIBIT C1

Purdue Pharma, L.P.

Case No. 19-23649

Bankruptcy Tax Consulting Services
February 1, 2020 through February 29, 2020
(includes time not previously billed)

Name	Date	Description	Hours	Rate	Amount
Ashley Armfield	02/17/20	Detailed review of summary related to results of trust call notes from last week (1.2) and notes from I. Hirsch (KPMG) meeting to determine updates that need to be made to cash tax model as of 2/17/2020 (0.9).	2.1	\$ 534	\$ 1,121.40
Jess Commisso	02/17/20	2.2 Associate review of Sackler family tree structure along with Project Malta third party debt table created by KPMG paraprofessional and concurrently performed updates - as needed.	2.2	\$ 350	\$ 770.00
Thomas Giordano	02/17/20	Revised depictions of the various steps in the structure deck disposition scenarios for Mundipharma Deutschland based on feedback received from P. DiMatteo (KPMG) as of 2/17/20.	2.2	\$ 350	\$ 770.00
Courtney Alonzo	02/17/20	(1.6) Research regarding certain potential tax deductions and the applicability of such to the Purdue contemplated structures; (1.0) draft of outline regarding the same.	2.6	\$ 534	\$ 1,388.40
Thomas Giordano	02/17/20	Revised draft US tax consequences / considerations related to the various steps in the structure deck disposition scenarios for Mundipharma Deutschland based on feedback from P. DiMatteo (KPMG) as of 2/17/20	2.8	\$ 350	\$ 980.00
Jess Commisso	02/17/20	3.1 Review and concurrently prepare new documentation provided by client as of 2/17, including Germany / Switzerland tax returns and transfer pricing materials, to share relevant tax information with the KPMG project teams.	3.1	\$ 350	\$ 1,085.00
Courtney Alonzo	02/17/20	(3.4) Perform research regarding flow through entities and certain tax credits.	3.4	\$ 534	\$ 1,815.60
Ashley Armfield	02/17/20	Revised the cash tax model to include updates relating to relevant settlement vehicle entities.	3.9	\$ 534	\$ 2,082.60
Courtney Alonzo	02/18/20	Review of research and related outline drafted (on previous day) and concurrently draft questions to be discussed related to certain tax credits.	0.5	\$ 534	\$ 267.00
Jess Commisso	02/18/20	Updates to Sackler family tree structure pursuant to determining members of Family A versus Family B (owners of Mundipharma trusts).	0.6	\$ 350	\$ 210.00
Jess Commisso	02/18/20	Creating excel tables displaying third party debt / preferred shareholder amounts in excel (based on provided by client documentation) pursuant to incorporation into the structure deck and cash tax model.	0.8	\$ 350	\$ 280.00
Claudio Mengotti	02/18/20	Manager review of additional Swiss data documentation uploaded to the VDA as of 2/18/2020 (especially Swiss tax returns) per request from D. Rowles (KPMG US)	1.0	\$ 730	\$ 730.00

EXHIBIT C1

Purdue Pharma, L.P.

Case No. 19-23649

Bankruptcy Tax Consulting Services
February 1, 2020 through February 29, 2020
(includes time not previously billed)

Name	Date	Description	Hours	Rate	Amount
Kevin Broich	02/18/20	0.6 Review of Purdue term sheet to gain insight related to the overall plan of emergence in order to properly assess the US federal income tax consequences of the plan of emergence; 0.5 review of taxable income impact as prepared by Norton Rose Fulbright LP to gain insight into anticipated tax consequences (as prepared by counsel) in each respective jurisdiction.	1.1	\$ 744	\$ 818.40
Thomas Giordano	02/18/20	Continue to revise draft US tax consequences and considerations related to asset sale and equity sale alternatives in the structure deck disposition scenarios for Mundipharma Deutschland.	1.2	\$ 350	\$ 420.00
Ashley Armfield	02/18/20	Updated the disposition for Canada (Purdue Pharma) per managing director review comments regarding updates for the trust implications associated with the disposition of certain Mundipharma assets.	1.6	\$ 534	\$ 854.40
Thomas Giordano	02/18/20	Conducted research with respect to various conveyance issues related to trust and estate planning in preparation for scenario planning	1.7	\$ 350	\$ 595.00
Jess Commisso	02/18/20	Incorporating updates requested by I. Hirsch (KPMG Managing Director) to the cash tax model as of 2/18/20.	1.8	\$ 350	\$ 630.00
Ashley Armfield	02/18/20	Updated disposition scenario for Switzerland (Mundipharma MEA GmbH) per managing director comments - related to trust updates pursuant to preparing cash tax model.	1.9	\$ 534	\$ 1,014.60
Thomas Giordano	02/18/20	Conducted research with respect to various potential deemed contribution issues (related to trust and estate planning) in preparation for scenario planning	2.1	\$ 350	\$ 735.00
Nick Morgan	02/18/20	2.2 Completed the upper tier portion of the US organizational structure chart per client deliverable.	2.2	\$ 350	\$ 770.00
Ashley Armfield	02/18/20	Meeting with A. Armfield and J. Commisso (both KPMG) to discuss model updates and considerations with respect to best approach related to the allocation of cash to preferred shareholders (Pharmaceutical Research Associates L.P versus not Pharmaceutical Research Associates L.P).	2.2	\$ 534	\$ 1,174.80
Jess Commisso	02/18/20	Meeting with A. Armfield and J. Commisso (both KPMG) to discuss model updates and considerations with respect to best approach related to the allocation of cash to preferred shareholders (Pharmaceutical Research Associates L.P versus not Pharmaceutical Research Associates L.P).	2.2	\$ 350	\$ 770.00

EXHIBIT C1

Purdue Pharma, L.P.

Case No. 19-23649

Bankruptcy Tax Consulting Services
February 1, 2020 through February 29, 2020
(includes time not previously billed)

Name	Date	Description	Hours	Rate	Amount
Christin Witt	02/18/20	Performed Manager review and concurrently reconcile information prepared by S. Stricker (KPMG Germany) regarding tax returns 2017 and 2018 for Krugmann GmbH, Mundipharma Deutschland GmbH & Co. KG, Mundipharma Verwaltungsgesellschaft GmbH, Mundipharma GmbH, Mundipharma Medical GmbH, Mundipharma Research GmbH & Co. KG, Mundichemie GmbH and Mundipharma Research Verwaltungs GmbH	2.8	\$ 650	\$ 1,820.00
Sonia Stricker	02/18/20	Analyze uploaded tax return / tax computation documentation for 2017 (1.7) and 2018 (1.8) for the following entities: Germany Verwaltungsgesellschaft GmbH, Krugmann GmbH, Mundichemie GmbH, Mundipharma Deutschland GmbH & Co. KG, Mundipharma GmbH, Mundipharma Medical GmbH, Mundipharma Research GmbH & Co. KG and Mundipharma Research Verwaltungsgesellschaft	3.5	\$ 380	\$ 1,330.00
Jess Commisso	02/18/20	Continued, from earlier in the day, to incorporate updates requested by I. Hirsch (KPMG Managing Director) to the cash tax model as of 2/18/20.	3.9	\$ 350	\$ 1,365.00
Ashley Armfield	02/18/20	Updates to cash tax model to reflect inclusion of various trust shareholders / sourcing of income.	3.9	\$ 534	\$ 2,082.60
Ashley Armfield	02/19/20	Updated the cash tax model contribution to settlement vehicle tab as it relates to the mandatory contribution per the term sheet.	0.4	\$ 534	\$ 213.60
Diego Lipp	02/19/20	Review of additional Purdue Swiss data in data room as of 2/19/2020 (especially Swiss tax returns) as requested by D. Rowles (KPMG UES)	0.5	\$ 640	\$ 320.00
Ashley Armfield	02/19/20	Call with I. Hirsch and A. Armfield (both KPMG) to review current version of cash tax model relating to the implementation of Pharmaceutical Research Associates Limited Partnership related versus Pharmaceutical Research Associates Limited Partnership non-related entities into the model.	0.9	\$ 534	\$ 480.60
Isaac Hirsch	02/19/20	Call with I. Hirsch and A. Armfield (both KPMG) to review current version of cash tax model relating to the implementation of Pharmaceutical Research Associates Limited Partnership related versus Pharmaceutical Research Associates Limited Partnership non-related entities into the model.	0.9	\$ 819	\$ 737.10
Howard Steinberg	02/19/20	Partner review of trust structure for the Mundipharma entities as it relates to the trusts, specifically related to entities in the US bankruptcy and the potential impact to such trusts when contributing cash to the settlement vehicle.	1.0	\$ 856	\$ 856.00

EXHIBIT C1

Purdue Pharma, L.P.

Case No. 19-23649

Bankruptcy Tax Consulting Services
February 1, 2020 through February 29, 2020
(includes time not previously billed)

Name	Date	Description	Hours	Rate	Amount
Michael Land	02/19/20	Performed senior associate review of Purdue cash tax model with specific regards to cash flow from disposition scenarios	1.1	\$ 534	\$ 587.40
Devon Rowles	02/19/20	Revised the US Purdue structure chart with regards to disposition analysis	1.1	\$ 350	\$ 385.00
Jess Commisso	02/19/20	Reviewed Virtual Data Room to identify all newly uploaded files as of 2/19/2020 (over 100 new uploads) to compile relevant documentation pursuant to sharing such information with the broader KPMG team.	1.4	\$ 350	\$ 490.00
Kevin Broich	02/19/20	1.2 Performed initial senior manager review of cash tax asset sale model to ensure the model accurately reflected the anticipated tax consequences of the contemplated asset sales in each respective jurisdiction	1.2	\$ 744	\$ 892.80
Kevin Broich	02/19/20	0.5 Review of project plan documents for purposes of aligning KPMG efforts on updating both the cash tax asset sale model and related slide deck depicting the contemplated plan of emergence.	0.5	\$ 744	\$ 372.00
Jess Commisso	02/19/20	Reviewed current version of Purdue cash tax model, as of 2/19/20 with focus on most recent updates / proper cash flow - as per new cash allocation methods.	1.8	\$ 350	\$ 630.00
Courtney Alonzo	02/19/20	(1.9) Performed detailed review of each contemplated structure to compile facts appropriate to apply foreign tax credit research for legal analysis.	1.9	\$ 534	\$ 1,014.60
Thomas Giordano	02/19/20	Continue research from 2/18/2020 with respect to various potential deemed contribution issues related to trust and estate planning in preparation for scenario planning	1.9	\$ 350	\$ 665.00
Michael Land	02/19/20	Perform a senior associate review of Purdue US structure for purposes of incorporating into our master deck	1.9	\$ 534	\$ 1,014.60
Michael Land	02/19/20	Reviewed virtual data room updates, as of 2/1/20, for purposes of identifying relevant tax information	1.9	\$ 534	\$ 1,014.60
Thomas Giordano	02/19/20	Continued (from 2/18/2020) to perform research with respect to various conveyance issues related to trust and estate planning in preparation for scenario planning	2.0	\$ 350	\$ 700.00
Michael Land	02/19/20	Perform senior associate review of Sackler family tree and related research for purposes of gaining insight regarding the family's citizenship and the potential tax consequences thereof	2.1	\$ 534	\$ 1,121.40
Nick Morgan	02/19/20	0.2 Finalized updates on the upper tier US structuring chart and 0.1 send to senior associates M. Land and A. Armfield (both KPMG) for review. 2.7: Created draft of the lower tier entities of the US Purdue structure chart for the client deliverable.	3.0	\$ 350	\$ 1,050.00

EXHIBIT C1

Purdue Pharma, L.P.

Case No. 19-23649

Bankruptcy Tax Consulting Services
February 1, 2020 through February 29, 2020
(includes time not previously billed)

Name	Date	Description	Hours	Rate	Amount
Courtney Alonzo	02/19/20	(2.8) Research regarding flow-through entities and certain foreign tax credits; (.3) Communication with P. DiMatteo (KPMG) regarding results of same.	3.1	\$ 534	\$ 1,655.40
Ashley Armfield	02/19/20	Continue, from earlier in the day, to update cash tax model to reflect inclusion of various trust shareholders / sourcing of income.	3.9	\$ 534	\$ 2,082.60
Jess Commisso	02/19/20	Reviewed Virtual Data Room to identify new client documentation uploaded as of 2/29 (over 100 new uploads) pursuant to sharing such information with the broader KPMG team.	3.9	\$ 350	\$ 1,365.00
Ashley Armfield	02/19/20	Revised the cash tax model for managing director comments from 2/19 relating to the allocation of income between entities.	3.9	\$ 534	\$ 2,082.60
Ashley Armfield	02/19/20	Updated the cash flow by entity allocation (i.e., to an entity directly contributing to the settlement vehicle, or not contributing directly) pursuant to preparing a cash tax model.	3.9	\$ 534	\$ 2,082.60
Jess Commisso	02/19/20	Updated the structure deck, specifically to Purdue Pharma Canada, Mundipharma Singapore Holding Pte Limited and Mundipharma MEA GmbH, pursuant to new information received as of 2/19 regarding trusts / entities which will be making ultimate distributions to the bankruptcy settlement vehicle.	3.9	\$ 350	\$ 1,365.00
Casey Nunez	02/20/20	Call with M. Hoffenberg (KPMG National Tax Corporate), T. Stone, P. Kunkel (both KPMG National Tax Trusts), H. Steinberg and C. Nunez (both KPMG M&A Tax), and I. Hirsch (KPMG International Tax) to discuss the U.S. and international trust tax implications and information needs as of 2/20/2020.	0.3	\$ 744	\$ 223.20
Howard Steinberg	02/20/20	Call with M. Hoffenberg (KPMG National Tax Corporate), T. Stone, P. Kunkel (both KPMG National Tax Trusts), H. Steinberg and C. Nunez (both KPMG M&A Tax), and I. Hirsch (KPMG International Tax) to discuss the U.S. and international trust tax implications and information needs as of 2/20/2020.	0.3	\$ 856	\$ 256.80
Isaac Hirsch	02/20/20	Call with M. Hoffenberg (KPMG National Tax Corporate), T. Stone, P. Kunkel (both KPMG National Tax Trusts), H. Steinberg and C. Nunez (both KPMG M&A Tax), and I. Hirsch (KPMG International Tax) to discuss the U.S. and international trust tax implications and information needs as of 2/20/2020.	0.3	\$ 819	\$ 245.70

EXHIBIT C1

Purdue Pharma, L.P.

Case No. 19-23649

Bankruptcy Tax Consulting Services
February 1, 2020 through February 29, 2020
(includes time not previously billed)

Name	Date	Description	Hours	Rate	Amount
Mark Hoffenberg	02/20/20	Call with M. Hoffenberg (KPMG National Tax Corporate), T. Stone, P. Kunkel (both KPMG National Tax Trusts), H. Steinberg and C. Nunez (both KPMG M&A Tax), and I. Hirsch (KPMG International Tax) to discuss the U.S. and international trust tax implications and information needs as of 2/20/2020.	0.3	\$ 980	\$ 294.00
Paul Kunkel	02/20/20	Call with M. Hoffenberg (KPMG National Tax Corporate), T. Stone, P. Kunkel (both KPMG National Tax Trusts), H. Steinberg and C. Nunez (both KPMG M&A Tax), and I. Hirsch (KPMG International Tax) to discuss the U.S. and international trust tax implications and information needs as of 2/20/2020.	0.3	\$ 744	\$ 223.20
Tracy Stone	02/20/20	(0.3) Call with M. Hoffenberg (KPMG National Tax Corporate), T. Stone, P. Kunkel (both KPMG National Tax Trusts), H. Steinberg and C. Nunez (both KPMG M&A Tax), and I. Hirsch (KPMG International Tax) to discuss the U.S. and international trust tax implications and information needs as of 2/20/2020; (0.2) review notes resulting from call related to trusts and concurrently revise info request with regards to same.	0.5	\$ 906	\$ 453.00
Kevin Broich	02/20/20	Perform senior manager review of updated cash tax asset sale model to ensure the model accurately reflected the anticipated tax consequences of the contemplated asset sales in each respective jurisdiction	0.4	\$ 744	\$ 297.60
Jess Commisso	02/20/20	Drafted list of all outstanding items pursuant to the cash tax model regarding the disposition of Mundipharma entities.	0.4	\$ 350	\$ 140.00
Courtney Alonzo	02/20/20	(.5) Perform research regarding flow-through entities and certain tax credits.	0.5	\$ 534	\$ 267.00
Diego Lipp	02/20/20	Communication with N. Meer (KPMG Switzerland) to discuss best approach to gather all relevant information to update Swiss tax compliance overview in connection with the request of D. Rowles (KPMG) dated 17 February 2020	0.5	\$ 640	\$ 320.00
Devon Rowles	02/20/20	Communication via email to KPMG member firms regarding new tax return documentation available on share site to facilitate timely and efficient review; Australia (.2); Switzerland (.2); Singapore (.2) and Netherlands (.2)	0.8	\$ 350	\$ 280.00
Jess Commisso	02/20/20	Compiled financial statement / tax return balance sheets for Mundipharma entities (in which we have created disposition scenarios) to identify any applicable information relevant to the cash tax model (i.e. tax basis).	0.8	\$ 350	\$ 280.00

EXHIBIT C1

Purdue Pharma, L.P.

Case No. 19-23649

Bankruptcy Tax Consulting Services

February 1, 2020 through February 29, 2020

(includes time not previously billed)

Name	Date	Description	Hours	Rate	Amount
Ashley Armfield	02/20/20	Meeting with I. Hirsch, A. Armfield, M. Land, J. Commisso (KPMG) regarding open items (i.e. withholding tax and ownership percentages) and changes in cash allocation to various trusts and entities pursuant to the disposition of Mundibiopharma Limited.	0.8	\$ 534	\$ 427.20
Isaac Hirsch	02/20/20	Meeting with I. Hirsch, A. Armfield, M. Land, J. Commisso (KPMG) regarding open items (i.e. withholding tax and ownership percentages) and changes in cash allocation to various trusts and entities pursuant to the disposition of Mundibiopharma Limited.	0.8	\$ 819	\$ 655.20
Jess Commisso	02/20/20	Meeting with I. Hirsch, A. Armfield, M. Land, J. Commisso (KPMG) regarding open items (i.e. withholding tax and ownership percentages) and changes in cash allocation to various trusts and entities pursuant to the disposition of Mundibiopharma Limited.	0.8	\$ 350	\$ 280.00
Michael Land	02/20/20	Meeting with I. Hirsch, A. Armfield, M. Land, J. Commisso (KPMG) regarding open items (i.e. withholding tax and ownership percentages) and changes in cash allocation to various trusts and entities pursuant to the disposition of Mundibiopharma Limited.	0.8	\$ 534	\$ 427.20
Jess Commisso	02/20/20	Updates to the structure deck as of 2/20/2020, specifically to Mundipharma MEA GmbH, pursuant to new information received regarding trusts / entities which will be making ultimate distributions to the bankruptcy settlement vehicle.	0.8	\$ 350	\$ 280.00
Pete DiMatteo	02/20/20	Review of open trust related points as well as next steps related to same in connection with trust tax analyses in connection with contemplated stock/asset sales and related distributions.	0.9	\$ 650	\$ 585.00
Denis Larkin	02/20/20	Discussion with D. Larkin and H. Lewis (both KPMG UK) regarding queries received from D. Rowles (KPMG US) related to ability to approximate tax basis, ability to distribute earnings and profits, existence of tax attributes and potential tax exposures - with regards to assumptions in the cash tax modeling.	1.0	\$ 566	\$ 566.00
Hanah Lewis	02/20/20	Discussion with D. Larkin and H. Lewis (both KPMG UK) regarding queries received from D. Rowles (KPMG US) related to ability to approximate tax basis, ability to distribute earnings and profits, existence of tax attributes and potential tax exposures - with regards to assumptions in the cash tax modeling.	1.0	\$ 239	\$ 239.00
Claudio Mengotti	02/20/20	Manager review of additional data in data room (especially Swiss tax returns) as indicated by D. Rowles (KPMG)	1.0	\$ 730	\$ 730.00

EXHIBIT C1

Purdue Pharma, L.P.

Case No. 19-23649

Bankruptcy Tax Consulting Services
February 1, 2020 through February 29, 2020
(includes time not previously billed)

Name	Date	Description	Hours	Rate	Amount
Ashley Armfield	02/20/20	Meeting with A. Armfield, M. Land, J. Commisso and I. Hirsch KPMG) regarding open items (i.e. withholding tax and ownership percentages) and changes in cash allocation to various trusts and entities pursuant to the disposition of Purdue Pharma Canada.	1.1	\$ 534	\$ 587.40
Isaac Hirsch	02/20/20	Meeting with A. Armfield, M. Land, J. Commisso and I. Hirsch KPMG) regarding open items (i.e. withholding tax and ownership percentages) and changes in cash allocation to various trusts and entities pursuant to the disposition of Purdue Pharma Canada.	1.1	\$ 819	\$ 900.90
Jess Commisso	02/20/20	Meeting with A. Armfield, M. Land, J. Commisso and I. Hirsch KPMG) regarding open items (i.e. withholding tax and ownership percentages) and changes in cash allocation to various trusts and entities pursuant to the disposition of Purdue Pharma Canada.	1.1	\$ 350	\$ 385.00
Michael Land	02/20/20	Meeting with A. Armfield, M. Land, J. Commisso and I. Hirsch KPMG) regarding open items (i.e. withholding tax and ownership percentages) and changes in cash allocation to various trusts and entities pursuant to the disposition of Purdue Pharma Canada.	1.1	\$ 534	\$ 587.40
Ashley Armfield	02/20/20	Meeting with I. Hirsch, A. Armfield, M. Land, J. Commisso (all KPMG) regarding open items (i.e. withholding tax and ownership percentages) and changes in cash allocation to various trusts and entities pursuant to the disposition of Mundipharma Deutschland GmbH & Co KG.	1.1	\$ 534	\$ 587.40
Isaac Hirsch	02/20/20	Meeting with I. Hirsch, A. Armfield, M. Land, J. Commisso (all KPMG) regarding open items (i.e. withholding tax and ownership percentages) and changes in cash allocation to various trusts and entities pursuant to the disposition of Mundipharma Deutschland GmbH & Co KG.	1.1	\$ 819	\$ 900.90
Jess Commisso	02/20/20	Meeting with I. Hirsch, A. Armfield, M. Land, J. Commisso (all KPMG) regarding open items (i.e. withholding tax and ownership percentages) and changes in cash allocation to various trusts and entities pursuant to the disposition of Mundipharma Deutschland GmbH & Co KG.	1.1	\$ 350	\$ 385.00
Michael Land	02/20/20	Meeting with I. Hirsch, A. Armfield, M. Land, J. Commisso (all KPMG) regarding open items (i.e. withholding tax and ownership percentages) and changes in cash allocation to various trusts and entities pursuant to the disposition of Mundipharma Deutschland GmbH & Co KG.	1.1	\$ 534	\$ 587.40
Hanah Lewis	02/20/20	Review of documents in the Purdue Data Room (specifically newly uploaded Mundipharma New Zealand Limited documents) in order to respond to email query received from D. Rowles (KPMG US) on 2/20/2020	1.1	\$ 239	\$ 262.90

EXHIBIT C1

Purdue Pharma, L.P.

Case No. 19-23649

Bankruptcy Tax Consulting Services
February 1, 2020 through February 29, 2020
(includes time not previously billed)

Name	Date	Description	Hours	Rate	Amount
Denis Larkin	02/20/20	(1.1) Performed Partner review and concurrently amend email drafted by H. Lewis (KPMG UK) in response to US queries related to cash tax modeling; (0.1) Drafted email to D. Rowles (KPMG US) to provide responses to her queries related to assumptions in the cash tax modeling.	1.2	\$ 566	\$ 679.20
Diego Lipp	02/20/20	Preparation of a tax compliance overview for Swiss entities according to the request of D. Rowles (KPMG US) on 17 February 2020	1.4	\$ 640	\$ 896.00
Isaac Hirsch	02/20/20	(1.5) Performed Managing Director review of updates to cash tax model to account for my comments - in preparation for meeting with project team to discuss next steps.	1.5	\$ 819	\$ 1,228.50
Hanah Lewis	02/20/20	Consideration related to various items (including ability to approximate tax basis, ability to distribute earnings and profits, existence of tax attributes and potential tax exposures) and concurrently draft a response to email query received from D. Rowles (KPMG US) - related to relevant assumptions to inform cash tax modelling.	1.8	\$ 239	\$ 430.20
Ashley Armfield	02/20/20	Meeting C. Nunez, I. Hirsch, A. Armfield, M. Land, J. Commisso (KPMG) to discuss cash allocations to various Mundipharma trusts and entities, including PRA LP, Rosebay Medical, and Beacon Company, pursuant to determining ultimate contributions to the bankruptcy settlement vehicle.	1.8	\$ 534	\$ 961.20
Casey Nunez	02/20/20	Meeting C. Nunez, I. Hirsch, A. Armfield, M. Land, J. Commisso (KPMG) to discuss cash allocations to various Mundipharma trusts and entities, including PRA LP, Rosebay Medical, and Beacon Company, pursuant to determining ultimate contributions to the bankruptcy settlement vehicle.	1.8	\$ 744	\$ 1,339.20
Isaac Hirsch	02/20/20	Meeting C. Nunez, I. Hirsch, A. Armfield, M. Land, J. Commisso (KPMG) to discuss cash allocations to various Mundipharma trusts and entities, including PRA LP, Rosebay Medical, and Beacon Company, pursuant to determining ultimate contributions to the bankruptcy settlement vehicle.	1.8	\$ 819	\$ 1,474.20
Jess Commisso	02/20/20	Meeting C. Nunez, I. Hirsch, A. Armfield, M. Land, J. Commisso (KPMG) to discuss cash allocations to various Mundipharma trusts and entities, including PRA LP, Rosebay Medical, and Beacon Company, pursuant to determining ultimate contributions to the bankruptcy settlement vehicle.	1.8	\$ 350	\$ 630.00

EXHIBIT C1

Purdue Pharma, L.P.

Case No. 19-23649

Bankruptcy Tax Consulting Services
February 1, 2020 through February 29, 2020
(includes time not previously billed)

Name	Date	Description	Hours	Rate	Amount
Michael Land	02/20/20	Meeting C. Nunez, I. Hirsch, A. Armfield, M. Land, J. Commisso (KPMG) to discuss cash allocations to various Mundipharma trusts and entities, including PRA LP, Rosebay Medical, and Beacon Company, pursuant to determining ultimate contributions to the bankruptcy settlement vehicle.	1.8	\$ 534	\$ 961.20
Jess Commisso	02/20/20	Reviewed Virtual Data Room to identify and concurrently compile new provided by client documentation as of 2/20 pursuant to sharing such information with the broader KPMG teams to facilitate tax analysis.	1.8	\$ 350	\$ 630.00
Thomas Giordano	02/20/20	Continue research, from 2/18/2020, with respect to various potential issues related to trust and estate planning in preparation for scenario planning	1.9	\$ 350	\$ 665.00
Sonia Stricker	02/20/20	Drafted summary of collected information from uploaded tax documents (i.e. tax attributes, capital contribution account, profit / loss, withholding tax) in a work sheet in excel format which was provided to D. Rowles (KPMG US) on February 21, 2020.	1.9	\$ 380	\$ 722.00
Thomas Giordano	02/20/20	Conducted research with respect to trust property conveyance and potential issues related to trust and estate planning in preparation for scenario planning	2.2	\$ 350	\$ 770.00
Casey Nunez	02/20/20	Performed Senior manager review the updated cash tax model as of 2/20/20.	2.3	\$ 744	\$ 1,711.20
Christin Witt	02/20/20	Manager review and concurrently reconcile information prepared by S. Stricker (KPMG Germany) regarding tax attributes, earnings and profits, withholding taxes, etc. for Krugmann GmbH, Mundipharma Deutschland GmbH & Co. KG, Mundipharma Verwaltungsgesellschaft GmbH, Mundipharma GmbH, Mundipharma Medical GmbH, Mundipharma Research GmbH & Co. KG, Mundichemie GmbH and Mundipharma Research Verwaltungs GmbH	2.9	\$ 650	\$ 1,885.00
Michael Land	02/20/20	Review of virtual data room information updates as of 2/20/2020 to determine relevancy for tax purposes	2.9	\$ 534	\$ 1,548.60
Ashley Armfield	02/20/20	Review of most current version of cash tax model prior to working session to identify points of discussion / outstanding items to be addressed.	3.2	\$ 534	\$ 1,708.80

EXHIBIT C1

Purdue Pharma, L.P.

Case No. 19-23649

Bankruptcy Tax Consulting Services
February 1, 2020 through February 29, 2020
(includes time not previously billed)

Name	Date	Description	Hours	Rate	Amount
Zafer Ülgen	02/20/20	Upon request of D. Rowles (KPMG United States) review the 2017 Dutch Corporate returns of Ladenburg BV, Mundipharma Bradenton BV, Accardi BV, Vaccaro BV, Tacca BV, Tenna BV and Mundipharma DC BV and expand our key findings. Based on this information identify tax attributes available at the level of the Dutch Purdue companies, ability to distribute dividends, potential tax exposures, identify inside tax basis and outside tax basis.	3.6	\$ 380	\$ 1,368.00
Michael Land	02/21/20	Review of intercompany payables summary for purposes of implementing into cash tax model	0.3	\$ 534	\$ 160.20
Claudio Mengotti	02/21/20	Consideration regarding inclusion of additional information in tax compliance overview for Swiss entities based on request for additional information in regard to the tax model being prepared by D. Rowles (KPMG US) on February 20, 2020	0.5	\$ 730	\$ 365.00
Ashley Armfield	02/21/20	Review of Mundipharma Deutschland GmbH & Co. KG 2018 financial statements with focus on company operations as well as relationship with silent partnership interest.	0.6	\$ 534	\$ 320.40
Jess Commisso	02/21/20	Reviewed new documentation in Virtual Data Room as of 2/21/2020 to identify determine relevant documentation pursuant to sharing with KPMG US and foreign project teams.	0.6	\$ 350	\$ 210.00
Ashley Armfield	02/21/20	Review of Napp Pharmaceutical Holdings Limited 2018 financial statements to gain insight related to company's book balance sheet / scope of operations.	0.7	\$ 534	\$ 373.80
Ashley Armfield	02/21/20	Review the Mundipharma Singapore Holding Pte Limited 2017 financial statements to gain insight related to company's book balance sheet / scope of operations.	0.7	\$ 534	\$ 373.80
Ashley Armfield	02/21/20	Reviewed the Mundipharma MEA GmbH 2018 financial statements to gain insight related to company's book balance sheet / scope of operations.	0.7	\$ 534	\$ 373.80
Ashley Armfield	02/21/20	Review of Mundipharma Medical Company (UK) 2018 financial statements to gain insight into the company's book balance sheet / scope of operations.	0.8	\$ 534	\$ 427.20
Ashley Armfield	02/21/20	Reviewed the Mundipharma DC BV 2018 financial statements to gain insight into the company's book balance sheet / scope of operations.	0.9	\$ 534	\$ 480.60
Tracy Stone	02/21/20	Performed Principal WNT review and concurrently revise the information request list relating to trusts - in preparation to provide to C. Nunez (KPMG).	1.0	\$ 906	\$ 906.00
Michael Land	02/21/20	Review of Purdue Pharma Inc. organizational chart for purposes of master disposition deck	1.1	\$ 534	\$ 587.40

EXHIBIT C1

Purdue Pharma, L.P.

Case No. 19-23649

Bankruptcy Tax Consulting Services

February 1, 2020 through February 29, 2020

(includes time not previously billed)

Name	Date	Description	Hours	Rate	Amount
Michael Land	02/21/20	Reviewed Singapore structure deck for purposes of gaining insight into disposition scenarios	1.1	\$ 534	\$ 587.40
Diego Lipp	02/21/20	Updated tax compliance overview for Swiss entities based on request for additional information in regard to the tax model being prepared by D. Rowles (KPMG US) on 20 February 2020	1.1	\$ 640	\$ 704.00
Jess Commisso	02/21/20	Updates to structure deck, specifically to Mundipharma MEA GmbH, Mundibiopharma Limited, and Mundipharma Medical Company, pursuant to new information regarding trusts / entities which will be making ultimate distributions to the bankruptcy settlement vehicle.	1.2	\$ 350	\$ 420.00
Thomas Giordano	02/21/20	Analyzed PBC files for comparison with KPMG created global organization structures to ensure consistency of ownership between the two, with respect to Mundipharma Deutschland.	1.5	\$ 350	\$ 525.00
Thomas Heubach	02/21/20	Performed Senior Manager review of the analysis executed / deliverable prepared by S. Stricker (KPMG Germany) on the tax returns along with related summary in work sheet.	1.5	\$ 750	\$ 1,125.00
Philipp Reer	02/21/20	Partner review of German Tax Information spreadsheet initially prepared by S. Stricker (KPMG Germany) and C. Witt (KPMG US).	1.6	\$ 765	\$ 1,224.00
Sonia Stricker	02/21/20	Prepared responses to questions raised by D. Rowles (KPMG US) regarding tax return information for the German entities (i.e. tax basis, earnings and profits, tax attributes and potential tax exposures) per email dated February 19, 2020.	1.6	\$ 380	\$ 608.00
Thomas Giordano	02/21/20	Conducted research with respect to trustee contributions to other trusts issues in preparation for scenario planning.	1.8	\$ 350	\$ 630.00
Thomas Giordano	02/21/20	Conducted research with respect to the Uniform Trust Code as it relates to certain distributions for the purposes of trust and estate planning in preparation for scenario planning	2.2	\$ 350	\$ 770.00
Jess Commisso	02/21/20	Creating a structure chart for Purdue Pharma US incorporating General Partner ownership pursuant to incorporation into the master structure deck for Mundipharma disposition analysis.	2.3	\$ 350	\$ 805.00
Nicolas Meer	02/21/20	Per direction from D. Lipp (KPMG Switzerland), prepared a tax compliance overview for Swiss entities -per request of D. Rowles (KPMG US) on 17 February 2020	3.0	\$ 295	\$ 885.00

EXHIBIT C1

Purdue Pharma, L.P.

Case No. 19-23649

Bankruptcy Tax Consulting Services
February 1, 2020 through February 29, 2020
(includes time not previously billed)

Name	Date	Description	Hours	Rate	Amount
Jess Commisso	02/21/20	Performing updates to the structure deck, specifically to Mundipharma MEA GmbH (1.3), Mundibiopharma Limited (1.3), and Mundipharma Medical Company (1.3), pursuant to new information regarding trusts / entities which will be making ultimate distributions to the bankruptcy settlement vehicle.	3.9	\$ 350	\$ 1,365.00
Maggie Scully	02/24/20	Continued (same day) to document all virtual data room updates as of 2/24/2020 into index-type document pursuant to creating a reference file to facilitate review/analysis of tax documents by project teams.	0.4	\$ 350	\$ 140.00
Nicolas Meer	02/24/20	Follow-up meeting with D. Lipp (KPMG Switzerland) to discuss Swiss tax due diligence including next steps to prepare a tax compliance overview) - for findings, please refer to our email to D. Rowles (KPMG US) on 02.28.20.	0.5	\$ 295	\$ 147.50
Diego Lipp	02/24/20	Follow-up meeting with N. Meer (KPMG Switzerland) to discuss Swiss tax due diligence including next steps to prepare a tax compliance overview) - for findings, please refer to our email to D. Rowles (KPMG US) on 02.28.20.	0.5	\$ 640	\$ 320.00
Pete DiMatteo	02/24/20	Performed analysis regarding foreign tax credits related to contemplated partnership distributions.	0.7	\$ 650	\$ 455.00
Nick Morgan	02/24/20	Reviewed transfer pricing reports along with filings with focus on client's tax profile with respect to certain international entities for the ultimate purpose of providing tax advice.	0.8	\$ 350	\$ 262.50
Ashley Armfield	02/24/20	Drafted email to project team to discuss priorities and next steps specifically related to the cash tax model; structuring deck, LEM tool; and review of transfer pricing documentation.	0.8	\$ 534	\$ 427.20
Ashley Armfield	02/24/20	Performed Senior Associate review of German tax structure for Mundipharma KG, including information provided by the KPMG tax team relating to the treatment of general and limited partners.	0.9	\$ 534	\$ 480.60
Ashley Armfield	02/24/20	Performed Senior Associate review of updates to the cash tax model (performed by J. Commisso - KPMG) with respect to certain tax and withholding issues.	1.1	\$ 534	\$ 587.40
Ashley Armfield	02/24/20	Meeting with A. Armfield and J. Commisso (both KPMG) to discuss and concurrently update the Purdue cash tax model based on director review comments with respect to certain tax and withholding issues.	1.6	\$ 534	\$ 854.40
Jess Commisso	02/24/20	Meeting with A. Armfield and J. Commisso (both KPMG) to discuss and concurrently update the Purdue cash tax model based on director review comments with respect to certain tax and withholding issues.	1.6	\$ 350	\$ 560.00

EXHIBIT C1

Purdue Pharma, L.P.

Case No. 19-23649

Bankruptcy Tax Consulting Services
February 1, 2020 through February 29, 2020
(includes time not previously billed)

Name	Date	Description	Hours	Rate	Amount
Thomas Giordano	02/24/20	Continue research, from 2/21/2020, with respect to certain trust issues in preparation for scenario planning	1.7	\$ 350	\$ 595.00
Ashley Armfield	02/24/20	Meeting with A. Armfield (KPMG) and J. Commisso (KPMG) to discuss updates required to cash tax model, per director commentary received with respect to certain tax and withholding issues.	1.8	\$ 534	\$ 961.20
Jess Commisso	02/24/20	Meeting with A. Armfield (KPMG) and J. Commisso (KPMG) to discuss updates required to cash tax model, per director commentary received with respect to certain tax and withholding issues.	1.8	\$ 350	\$ 630.00
Michael Land	02/24/20	Review of virtual data room updates, as of 2/24/20, for purposes of identifying relevant tax information	1.9	\$ 534	\$ 1,014.60
Devon Rowles	02/24/20	Updated the Germany structure deck with regards to asset/stock dispositions and related tax consequences- based on Senior Associate review comments received as of 2/24/20.	1.9	\$ 350	\$ 665.00
Jess Commisso	02/24/20	Updated the Purdue cash tax model based on results of discussion (on same day with A. Armfield - KPMG) related to commentary received with respect to certain tax and withholding issues.	2.0	\$ 350	\$ 700.00
Devon Rowles	02/24/20	Review new documents in the virtual data room, as of 2/24/2020, to determine if they are relevant for the disposition of the Mundipharma entities	2.3	\$ 350	\$ 805.00
Thomas Giordano	02/24/20	Revised draft US tax consequences / related considerations related to certain partnership tax issues for structure deck disposition scenarios with respect to German subsidiary	2.3	\$ 350	\$ 805.00
Isaac Hirsch	02/24/20	Conference call with I. Hirsch, P. DiMatteo, and T. Giordano (all KPMG) to review (and discuss possible revisions to) disposition scenario planning deck with respect to German subsidiary.	2.7	\$ 819	\$ 2,211.30
Pete DiMatteo	02/24/20	Conference call with I. Hirsch, P. DiMatteo, and T. Giordano (all KPMG) to review (and discuss possible revisions to) disposition scenario planning deck with respect to German subsidiary.	2.7	\$ 650	\$ 1,755.00
Thomas Giordano	02/24/20	Conference call with I. Hirsch, P. DiMatteo, and T. Giordano (all KPMG) to review (and discuss possible revisions to) disposition scenario planning deck with respect to German subsidiary.	2.7	\$ 350	\$ 945.00
Nicolas Meer	02/24/20	Review and concurrently compile updated documentation in the virtual data room (VDR) as of 2/24/2020 to facilitate tax analysis as instructed by D. Lipp (KPMG)	3.4	\$ 295	\$ 1,003.00

EXHIBIT C1

Purdue Pharma, L.P.

Case No. 19-23649

Bankruptcy Tax Consulting Services

February 1, 2020 through February 29, 2020

(includes time not previously billed)

Name	Date	Description	Hours	Rate	Amount
Devon Rowles	02/24/20	Revised the Switzerland structure deck with regards to asset/stock dispositions as well as related tax consequences with regards to review comments received from KPMG Senior Associate (M. Land)	3.9	\$ 350	\$ 1,365.00
Maggie Scully	02/24/20	Summarized all virtual data room updates as of 2/24/2020 into index-type document pursuant to creating a reference file to facilitate review/analysis of tax documents by project teams.	3.9	\$ 350	\$ 1,365.00
Jess Commisso	02/24/20	Updates to the Purdue cash tax model, specifically to Purdue Pharma Canada, to break out the appropriate cash distribution as well as the related taxes between general and limited partners in order to clarify order of cash flow.	3.9	\$ 350	\$ 1,365.00
Devon Rowles	02/25/20	Created a template for Singapore's information request list to facilitate tracking of updates related to new relevant tax information (requested and received).	0.4	\$ 350	\$ 140.00
Sayan Basak	02/25/20	Discussion with M. Low (KPMG) in relation to the Singapore tax implications arising out of the sale of the assets located in Singapore.	0.5	\$ 380	\$ 190.00
Marissa Low	02/25/20	Discussion with S. Basak (KPMG) in relation to the Singapore tax implications arising out of the sale of the assets located in Singapore.	0.5	\$ 730	\$ 365.00
Maggie Scully	02/25/20	Continue (from same day) to document all virtual data room updates as of 2/25/2020 into index-type document pursuant to creating a reference file to facilitate review/analysis of tax documents by project teams.	0.7	\$ 350	\$ 245.00
Jess Commisso	02/25/20	Correspondence with KPMG member firms regarding tax return analysis requests pursuant to incorporation of provided by client information into the cash tax model / structure deck.	0.8	\$ 350	\$ 280.00
Devon Rowles	02/25/20	Continue (same day) to perform review of documents in the virtual data room, as of 2/25/2020, to determine if they are relevant for the disposition of the Mundipharma entities	0.9	\$ 350	\$ 315.00
Ashley Armfield	02/25/20	Performed Senior Associate review of updates to cash tax model (performed by J. Commisso) for certain tax issues in connection with distributions.	0.9	\$ 534	\$ 480.60
Sayan Basak	02/25/20	Reviewing the background facts in relation to the Chapter 11 Bankruptcy proceedings of Purdue Pharma LP with regards to project requirements.	1.0	\$ 380	\$ 380.00
Isaac Hirsch	02/25/20	Managing Director review of updates to structure deck as of 2/25/20 with regards to UK sale scenarios	1.1	\$ 819	\$ 900.90

EXHIBIT C1

Purdue Pharma, L.P.

Case No. 19-23649

Bankruptcy Tax Consulting Services
February 1, 2020 through February 29, 2020
(includes time not previously billed)

Name	Date	Description	Hours	Rate	Amount
Devon Rowles	02/25/20	Updating the information request list to include documentation requested / received as of 2/25/202 in the virtual data room with regards to disposition of Mundipharma entities	1.1	\$ 350	\$ 385.00
Ashley Armfield	02/25/20	Updated the Purdue cash tax model for withholding tax considerations on the breakout of cash distributions for Canada (1 entity).	1.2	\$ 534	\$ 640.80
Ashley Armfield	02/25/20	Meeting with A. Armfield and J. Commisso (both KPMG) to discuss model updates, including the incorporation of certain tax issues in connection with cash distributions for Canada (1 entity), Germany (1 entity) and UK (3 entities) jurisdictions.	1.3	\$ 534	\$ 694.20
Jess Commisso	02/25/20	Meeting with A. Armfield and J. Commisso (both KPMG) to discuss model updates, including the incorporation of certain tax issues in connection with cash distributions for Canada (1 entity), Germany (1 entity) and UK (3 entities) jurisdictions.	1.3	\$ 350	\$ 455.00
Howard Steinberg	02/25/20	Partner review of documentation received to date with respect to the entities listed in the Norton Rose calculations, specifically including the following jurisdictions: UK, Germany, Switzerland.	1.3	\$ 856	\$ 1,112.80
Courtney Alonzo	02/25/20	0.6 Senior Associate review of updated slide decks prepared to reflect the various options for sale of relevant entities; 0.3 Communication with P. DiMatteo (KPMG) to convey status update related to same; 0.6 Performed additional background research regarding certain tax credits.	1.5	\$ 534	\$ 801.00
Sayan Basak	02/25/20	Continued, on same day, to perform Associate review of the term sheet dated 10/08/2019 filed by Purdue Pharma LP to the Ad Hoc Committee in relation to the Chapter 11 Bankruptcy to gain insight into the structuring of the transaction with focus on tax implications, if any, on the Singapore entities.	1.6	\$ 380	\$ 608.00
Ashley Armfield	02/25/20	Revised the Purdue cash tax model assumptions based on model updates relating to the allocation of income between relevant families.	1.7	\$ 534	\$ 907.80
Thomas Giordano	02/25/20	Performed updates to structure deck disposition scenarios for Napp Pharmaceuticals following conference with KPMG international tax team.	1.8	\$ 350	\$ 630.00
Devon Rowles	02/25/20	Updating the matrix of financial statements/transfer pricing/tax return (by entity and by country) with regards to most recent round of documents in virtual data room	1.8	\$ 350	\$ 630.00

EXHIBIT C1

Purdue Pharma, L.P.

Case No. 19-23649

Bankruptcy Tax Consulting Services

February 1, 2020 through February 29, 2020

(includes time not previously billed)

Name	Date	Description	Hours	Rate	Amount
Michael Land	02/25/20	Perform senior associate level review of structure deck for purposes of determining proper disposition scenarios for UK	2.0	\$ 534	\$ 1,068.00
Jess Commisso	02/25/20	Update Purdue cash tax model with regards to certain tax issues in connection with cash distributions for Germany (1 entity) and UK (3 entities) jurisdictions.	2.1	\$ 350	\$ 735.00
Thomas Giordano	02/25/20	Performed updates to structure deck disposition scenarios for Mundibiopharma following conference with KPMG international tax team.	2.2	\$ 350	\$ 770.00
Nick Morgan	02/25/20	Revised notes in excel with respect to transfer pricing reports in order calculate tax exposures per client deliverable.	2.2	\$ 350	\$ 770.00
Thomas Giordano	02/25/20	Updated the structure deck disposition scenarios for Mundipharma Medical with regards to results of meeting with KPMG International tax team.	2.2	\$ 350	\$ 770.00
Devon Rowles	02/25/20	Revised the UK structure deck with regards to asset/stock dispositions (and related tax consequences) based on reviewed comments received from senior associate as of 2/25.	2.3	\$ 350	\$ 805.00
Michael Land	02/25/20	Review of virtual data room updates, as of 2/25/20, for purposes of identifying relevant tax information	2.4	\$ 534	\$ 1,281.60
Thomas Giordano	02/25/20	Revised the structure deck disposition scenarios for Mundipharma Deutschland GmbH & Co. KG based on results of conference with International Tax team	2.7	\$ 350	\$ 945.00
Sayan Basak	02/25/20	Perform Associate review of the term sheet dated 10/08/2019 filed by Purdue Pharma LP to the Ad Hoc Committee in relation to the Chapter 11 Bankruptcy to gain insight into the structuring of the transaction with focus on tax implications, if any, on the Singapore entities.	2.9	\$ 380	\$ 1,102.00
Jess Commisso	02/25/20	Performing updates to the cash tax model, specifically for Mundipharma KG, to incorporate accurate distribution of cash to upper tier ownership / apply appropriate withholding rates.	3.2	\$ 350	\$ 1,120.00
Jess Commisso	02/25/20	Updates to the cash tax model, specifically for Purdue Pharma Canada, to incorporate correct distribution of cash to upper tier ownership / apply appropriate withholding rates.	3.4	\$ 350	\$ 1,190.00
Maggie Scully	02/25/20	Documented all virtual data room updates as of 2/25/2020 into index-type document pursuant to creating a reference file to facilitate review/analysis of tax documents by project teams.	3.9	\$ 350	\$ 1,365.00

EXHIBIT C1

Purdue Pharma, L.P.

Case No. 19-23649

Bankruptcy Tax Consulting Services
February 1, 2020 through February 29, 2020
(includes time not previously billed)

Name	Date	Description	Hours	Rate	Amount
Devon Rowles	02/25/20	Reviewed new documents in the virtual data room, as of 2/25/2020, to determine if they are relevant for the disposition of the Mundipharma entities	3.9	\$ 350	\$ 1,365.00
Ashley Armfield	02/26/20	Senior Associate review of transfer pricing notes prepared by N. Morgan (KPMG) to date with focus on Mundipharma business and revenue streams.	0.4	\$ 534	\$ 213.60
Simon Juon	02/26/20	Partner review of documentation prepared by C. Mengotti (KPMG Switzerland) and D. Lipp (KPMG Switzerland) specifically relating to the KPMG US request to provide our initial review of inside tax basis, earnings and profits, tax attributes, and any potential tax exposures.	0.5	\$ 985	\$ 492.50
Jess Commisso	02/26/20	(0.8) Performed research on withholding rates between relevant Mundipharma jurisdictions pursuant to the incorporation to the cash tax model.	0.8	\$ 350	\$ 280.00
Thomas Giordano	02/26/20	Revise the structure deck disposition scenarios for Mundipharma Deutschland GmbH & Co. KG with regards to results of second review by International Tax team	0.8	\$ 350	\$ 280.00
Karl Tong	02/26/20	Responded to email from D. Rowles (KPMG US) regarding the following (from a Chinese tax perspective); tax basis assumption (0.4); abilities to distribute dividends (0.2); tax attributes available (0.3); and potential tax exposure (0.2)	1.1	\$ 594	\$ 653.40
Thomas Giordano	02/26/20	Updated structure deck disposition scenarios for Mundipharma Medical Company Limited based on follow up feedback from P. DiMatteo (KPMG).	1.8	\$ 350	\$ 630.00
Diego Lipp	02/26/20	Performed Swiss tax due diligence by performing Senior Associate review of findings (prepared by N. Meer KPMG Switzerland) for data in KPMG Share site relating to the 13 Swiss entities.	2.0	\$ 640	\$ 1,280.00
Nicolas Meer	02/26/20	Review of KPMG Share site for documentation relating to Swiss entities (13 entities total) pursuant to determining documentation received to date - to provide an update to the KPMG US information request list.	2.0	\$ 295	\$ 590.00
Devon Rowles	02/26/20	Continued to revise the 130 page master structure deck with specific regards to asset/stock dispositions as well as related tax consequences, based on review comments received from Senior Associate - as began earlier in the day.	2.1	\$ 350	\$ 735.00
Maggie Scully	02/26/20	Documented all virtual data room updates as of 2/26/2020 into index-type document pursuant to creating a reference file to facilitate review/analysis of tax documents by project teams.	2.3	\$ 350	\$ 805.00

EXHIBIT C1

Purdue Pharma, L.P.

Case No. 19-23649

Bankruptcy Tax Consulting Services

February 1, 2020 through February 29, 2020

(includes time not previously billed)

Name	Date	Description	Hours	Rate	Amount
Courtney Alonzo	02/26/20	2.4 Performed research regarding certain tax credits / applicability of various internal revenue code sections regarding tax credits.	2.4	\$ 534	\$ 1,281.60
Casey Nunez	02/26/20	Performed Senior Manager review of latest round of updates to the Purdue Pharma updated cash tax model as of 2/26/2020.	2.6	\$ 744	\$ 1,934.40
Thomas Giordano	02/26/20	Revised the structure deck disposition scenarios for Mundibiopharma Limited based on follow up feedback from P. DiMatteo (KPMG)	2.6	\$ 350	\$ 910.00
Ashley Armfield	02/26/20	Senior Associate review of latest version of cash tax model (with regards to German / United Kingdom updates) made by J. Commisso (KPMG).	2.9	\$ 534	\$ 1,548.60
Nick Morgan	02/26/20	Review and concurrently summarize client's EY Malta reports along with certain 2018 transfer pricing reports in order to gain insight regarding legal entity structuring, cash flows, supply chain, and transfer pricing issues.	3.3	\$ 350	\$ 1,155.00
Diego Lipp	02/26/20	Preparation of entity attribute table pursuant to providing KPMG US with information inside tax basis, earnings and profits, tax attributes, and any potential tax exposures for all 13 Swiss entities.	3.5	\$ 640	\$ 2,240.00
Jess Commisso	02/26/20	Updated the Purdue cash tax model, specifically for Mundibiopharma Limited, to incorporate correct distribution of cash to upper tier ownership and apply appropriate withholding rates.	3.5	\$ 350	\$ 1,225.00
Jess Commisso	02/26/20	(3.7) Updates to the Purdue cash tax model, specifically Mundipharma KG, to incorporate correct distribution of cash to upper tier ownership and apply appropriate withholding rates.	3.7	\$ 350	\$ 1,295.00
Thomas Giordano	02/26/20	1.8 Performed revisions for structure deck disposition scenarios for Napp Pharmaceuticals post second review by International Tax team; 2.0 Conducted research on foreign tax credit regulations related to attribution of foreign branch income to partnerships.	3.8	\$ 350	\$ 1,330.00
Sayan Basak	02/26/20	Continue, from same day, to perform Associate review and concurrently draft initial comments (due diligence) on the Financial Statements, Tax Computations, Tax Returns, Notice of Assessments of the entities based out of Singapore for fiscal year 2017 and 2018.	3.9	\$ 380	\$ 1,482.00
Sayan Basak	02/26/20	Perform Associate review and concurrently draft initial comments (due diligence) on the Financial Statements, Tax Computations, Tax returns, Notice of Assessments of the five Mundipharma entities for fiscal year 2017 and 2018 based out of Singapore.	3.9	\$ 380	\$ 1,482.00

EXHIBIT C1

Purdue Pharma, L.P.

Case No. 19-23649

Bankruptcy Tax Consulting Services
February 1, 2020 through February 29, 2020
(includes time not previously billed)

Name	Date	Description	Hours	Rate	Amount
Devon Rowles	02/26/20	Revised the 130 page master structure deck with specific regards to asset/stock dispositions as well as related tax consequences, with regards to review comments received from Senior Associate	3.9	\$ 350	\$ 1,365.00
Sayan Basak	02/27/20	Preparing Information Request List (IRL) to request for additional tax documentation in relation to Singapore entities.	0.2	\$ 380	\$ 76.00
Isaac Hirsch	02/27/20	(0.5) Prepare for phone call with M. Hoffenberg, T. Stone, P. Kunkel, I. Hirsch, M. Land, A. Armfield and J. Commisso (all KPMG employees) to discuss tax analysis of flow of funds through trusts - by reviewing Norton Rose cash tax cost calculations	0.5	\$ 819	\$ 409.50
Thomas Giordano	02/27/20	Conducted research on controlled foreign corporation rules.	0.6	\$ 350	\$ 210.00
Jess Commisso	02/27/20	Compiled call notes detailing results of discussions with KPMG Washington National Tax members related to trust information - pursuant to sharing with project team.	0.8	\$ 350	\$ 280.00
Thomas Giordano	02/27/20	Continue performing revisions for structure deck disposition scenarios for Mundipharma Deutschland GmbH & Co. KG based on follow up feedback from P. DiMatteo	0.8	\$ 350	\$ 280.00
Sayan Basak	02/27/20	Continue, from same day, to perform Associate review and draft initial comments (due diligence) on the Financial Statements, Tax Computations, Tax returns, Notice of Assessments of the entities based out of Singapore for fiscal year 2017 and 2018.	1.0	\$ 380	\$ 380.00
Sayan Basak	02/27/20	Discussion with M. Low (KPMG Singapore) regarding findings related to review of documents provided (i.e. Financial Statements, Tax Computations, Tax returns).	1.0	\$ 380	\$ 380.00
Marissa Low	02/27/20	Discussion with S. Basak (KPMG Singapore) regarding findings related to review of documents provided (i.e. Financial Statements, Tax Computations, Tax returns).	1.0	\$ 730	\$ 730.00
Courtney Alonzo	02/27/20	1.1 Performed additional research related to certain tax credits and pass-through entities.	1.1	\$ 534	\$ 587.40
Ashley Armfield	02/27/20	Discussion with A. Armfield, M. Land and J. Commisso (KPMG) regarding updates to the Purdue cash tax model including which entities are responsible for gross up payments and the integration of certain deductions into the US tax calculation.	1.1	\$ 534	\$ 587.40
Jess Commisso	02/27/20	Discussion with A. Armfield, M. Land and J. Commisso (KPMG) regarding updates to the Purdue cash tax model including which entities are responsible for gross up payments and the integration of certain deductions into the US tax calculation.	1.1	\$ 350	\$ 385.00

EXHIBIT C1

Purdue Pharma, L.P.

Case No. 19-23649

Bankruptcy Tax Consulting Services
February 1, 2020 through February 29, 2020
(includes time not previously billed)

Name	Date	Description	Hours	Rate	Amount
Michael Land	02/27/20	Discussion with A. Armfield, M. Land and J. Commisso (KPMG) regarding updates to the Purdue cash tax model including which entities are responsible for gross up payments and the integration of certain deductions into the US tax calculation.	1.1	\$ 534	\$ 587.40
Thomas Giordano	02/27/20	Continue, from 2/26/2020, updates for structure deck disposition scenarios for a UK subsidiary based on follow up feedback from P. DiMatteo	1.2	\$ 350	\$ 420.00
Ashley Armfield	02/27/20	Call with M. Hoffenberg, T. Stone, P. Kunkel, I. Hirsch, M. Land, A. Armfield and J. Commisso (all KPMG employees) to discuss the inclusion of Sackler family trusts in the cash tax model and the various scenarios of tax implications that could arise.	1.3	\$ 534	\$ 694.20
Isaac Hirsch	02/27/20	Call with M. Hoffenberg, T. Stone, P. Kunkel, I. Hirsch, M. Land, A. Armfield and J. Commisso (all KPMG employees) to discuss the inclusion of Sackler family trusts in the cash tax model and the various scenarios of tax implications that could arise.	1.3	\$ 819	\$ 1,064.70
Jess Commisso	02/27/20	Call with M. Hoffenberg, T. Stone, P. Kunkel, I. Hirsch, M. Land, A. Armfield and J. Commisso (all KPMG employees) to discuss the inclusion of Sackler family trusts in the cash tax model and the various scenarios of tax implications that could arise.	1.3	\$ 350	\$ 455.00
Mark Hoffenberg	02/27/20	Call with M. Hoffenberg, T. Stone, P. Kunkel, I. Hirsch, M. Land, A. Armfield and J. Commisso (all KPMG employees) to discuss the inclusion of Sackler family trusts in the cash tax model and the various scenarios of tax implications that could arise.	1.3	\$ 980	\$ 1,274.00
Michael Land	02/27/20	Call with M. Hoffenberg, T. Stone, P. Kunkel, I. Hirsch, M. Land, A. Armfield and J. Commisso (all KPMG employees) to discuss the inclusion of Sackler family trusts in the cash tax model and the various scenarios of tax implications that could arise.	1.3	\$ 534	\$ 694.20
Paul Kunkel	02/27/20	Call with M. Hoffenberg, T. Stone, P. Kunkel, I. Hirsch, M. Land, A. Armfield and J. Commisso (all KPMG employees) to discuss the inclusion of Sackler family trusts in the cash tax model and the various scenarios of tax implications that could arise.	1.3	\$ 744	\$ 967.20
Tracy Stone	02/27/20	Call with M. Hoffenberg, T. Stone, P. Kunkel, I. Hirsch, M. Land, A. Armfield and J. Commisso (all KPMG employees) to discuss the inclusion of Sackler family trusts in the cash tax model and the various scenarios of tax implications that could arise.	1.3	\$ 906	\$ 1,177.80

EXHIBIT C1

Purdue Pharma, L.P.

Case No. 19-23649

Bankruptcy Tax Consulting Services

February 1, 2020 through February 29, 2020

(includes time not previously billed)

Name	Date	Description	Hours	Rate	Amount
Thomas Giordano	02/27/20	Conducted research on certain income attribution rules and certain tax credit rules.	1.4	\$ 350	\$ 490.00
Tracy Stone	02/27/20	Performed Principal WNT review Swiss Mundipharma tax computations	1.5	\$ 906	\$ 1,359.00
Thomas Giordano	02/27/20	Continue from 2/26/2020 revisions for structure deck disposition scenarios for a UK subsidiary based on follow up feedback from P. DiMatteo and I. Hirsch (both KPMG)	1.9	\$ 350	\$ 665.00
Thomas Giordano	02/27/20	Conducted additional research on certain income attribution rules and certain tax credit rules.	2.1	\$ 350	\$ 735.00
Ashley Armfield	02/27/20	Performed Senior Associate review and concurrently comment on disposition of Mundipharma KG in cash tax model.	2.3	\$ 534	\$ 1,228.20
Ashley Armfield	02/27/20	Perform Senior Associate review and concurrently comment on disposition of Mundibiopharma entity in cash tax model.	2.6	\$ 534	\$ 1,388.40
Claudio Mengotti	02/27/20	Manager level preparation of document relating to preliminary findings / potential issue spotting fro various Swiss entities.	2.7	\$ 730	\$ 1,971.00
Jess Commisso	02/27/20	Additional revisions to the cash tax model specifically for Mundipharma MEA GmbH, to incorporate correct distribution of cash to upper tier ownership and apply appropriate withholding rates.	2.9	\$ 350	\$ 1,015.00
Jess Commisso	02/27/20	Revisions to the cash tax model, specifically for Mundipharma KG, to incorporate correct distribution of cash to upper tier ownership and apply appropriate withholding rates.	2.9	\$ 350	\$ 1,015.00
Diego Lipp	02/27/20	Senior Associate preparation of document relating to preliminary findings / potential issue spotting, including consideration given to the application of thin-capitalization, insufficient residual profits, and non-arm's length remuneration for various Swiss entities.	3.5	\$ 640	\$ 2,240.00
Nick Morgan	02/27/20	3.6 Drafted summaries of 2018 transfer pricing reports for specific client entities with focus on cash flows / potential tax exposures.	3.6	\$ 350	\$ 1,260.00
Devon Rowles	02/27/20	Continue (same day) to revise the Germany structure deck with regards to updates related to asset/stock disposition analysis / tax consequences as of 2/27/2020.	3.6	\$ 350	\$ 1,260.00
Devon Rowles	02/27/20	Revised Germany structure deck with regards to updates related to asset/stock disposition analysis / tax consequences as of 2/27/2020.	3.9	\$ 350	\$ 1,365.00
Nick Morgan	02/28/20	Documented page numbers on transfer pricing reports in master transfer pricing deal note workbook in order link significant information for modeling purposes.	0.4	\$ 350	\$ 140.00

EXHIBIT C1

Purdue Pharma, L.P.

Case No. 19-23649

Bankruptcy Tax Consulting Services

February 1, 2020 through February 29, 2020

(includes time not previously billed)

Name	Date	Description	Hours	Rate	Amount
Isaac Hirsch	02/28/20	(0.6) Performed managing director review of updates to analysis of deductibility of settlement proceeds as of 2/28/20.	0.6	\$ 819	\$ 491.40
Claudio Mengotti	02/28/20	Communication with S. Juon (KPMG Switzerland) on likelihood / extent of potential findings in connection with Swiss tax due diligence performed with regards to original request from D. Rowles (KPMG US) on 02.26.20.	0.6	\$ 730	\$ 438.00
Sayan Basak	02/28/20	Performed Associate level review of the Financial Statements of the Singapore entities for determining the tax basis in the entities.	1.0	\$ 380	\$ 380.00
Michael Land	02/28/20	Perform senior associate review of updates, as of 2/28/20, to structure deck regarding Netherlands disposition scenarios for purposes of comparing stock versus asset sale	1.0	\$ 534	\$ 534.00
Michael Land	02/28/20	Perform senior associate review of updates, as of 2/28/20, to structure deck regarding Switzerland disposition scenarios for purposes of comparing stock versus asset sale	1.1	\$ 534	\$ 587.40
Michael Land	02/28/20	Performed senior associate review of updates, as of 2/28/20, to structure deck regarding Canada disposition scenarios for purposes of comparing stock versus asset sale	1.1	\$ 534	\$ 587.40
Michael Land	02/28/20	Performed senior associate review of updates, as of 2/28/20, to structure deck regarding Singapore disposition scenarios for purposes of comparing stock versus asset sale	1.2	\$ 534	\$ 640.80
Courtney Alonzo	02/28/20	0.5 Continued (from previous day) to perform research regarding certain tax credits; 0.8 draft narrative regarding availability of certain tax credits and impact to the contemplated structures.	1.3	\$ 534	\$ 694.20
Thomas Giordano	02/28/20	Continue (same day) to revise the disposition scenario planning deck for UK subsidiary based on results of 2/28/2020 conference with I. Hirsch and P. DiMatteo (both KPMG).	1.3	\$ 350	\$ 455.00
Pete DiMatteo	02/28/20	Discussion between P. DiMatteo (KPMG) and T. Giordano (KPMG) regarding revisions to disposition scenario planning deck for UK subsidiary	1.3	\$ 650	\$ 845.00
Thomas Giordano	02/28/20	Discussion between P. DiMatteo (KPMG) and T. Giordano (KPMG) regarding revisions to disposition scenario planning deck for UK subsidiary	1.3	\$ 350	\$ 455.00
Ashley Armfield	02/28/20	Meeting with A. Armfield and J. Commisso (both KPMG) to review and concurrently discuss cash tax model updates for Mundibiopharma Limited as of 2/28/20.	1.3	\$ 534	\$ 694.20
Jess Commisso	02/28/20	Meeting with A. Armfield and J. Commisso (both KPMG) to review and concurrently discuss cash tax model updates for Mundibiopharma Limited as of 2/28/20.	1.3	\$ 350	\$ 455.00

EXHIBIT C1

Purdue Pharma, L.P.

Case No. 19-23649

Bankruptcy Tax Consulting Services
February 1, 2020 through February 29, 2020
(includes time not previously billed)

Name	Date	Description	Hours	Rate	Amount
Isaac Hirsch	02/28/20	Discussion with I. Hirsch, P. DiMatteo, and T. Giordano (all KPMG) to discuss status / updates to disposition scenario planning deck for UK subsidiary.	1.5	\$ 819	\$ 1,228.50
Pete DiMatteo	02/28/20	Discussion with I. Hirsch, P. DiMatteo, and T. Giordano (all KPMG) to discuss status / updates to disposition scenario planning deck for UK subsidiary.	1.5	\$ 650	\$ 975.00
Thomas Giordano	02/28/20	Discussion with I. Hirsch, P. DiMatteo, and T. Giordano (all KPMG) to discuss status / updates to disposition scenario planning deck for UK subsidiary.	1.5	\$ 350	\$ 525.00
Simon Juon	02/28/20	Partner review of entity attribute table (prepared by C. Mengotti and D. Lipp (both KPMG Switzerland) pursuant to providing KPMG US with information related to inside tax basis, earnings and profits, tax attributes, and any potential tax exposures for all 13 Swiss entities	1.5	\$ 985	\$ 1,477.50
Jess Commisso	02/28/20	Updates to the cash tax model, specifically for Mundibiopharma Limited and Mundipharma Medical Company Limited, to incorporate accurate distribution of cash to upper tier ownership and apply appropriate withholding rates.	1.6	\$ 350	\$ 560.00
Diego Lipp	02/28/20	Senior Associate review of preliminary findings / potential tax issues with respect to thin-capitalization, insufficient residual profits, and non-arm's length remuneration for various Swiss entities.	1.7	\$ 640	\$ 1,088.00
Claudio Mengotti	02/28/20	Analyzed and concurrently noted findings (as requested by D. Rowles KPMG US) relating to preliminary findings and potential issue spotting with respect to thin-capitalization, insufficient residual profits, and non-arm's length remuneration for various Swiss entities.	1.9	\$ 730	\$ 1,387.00
Claudio Mengotti	02/28/20	Performed Manager review of documentation prepared by D. Lipp (KPMG Switzerland) including information providing a table of inside tax basis, earnings and profits, tax attributes, and any potential tax exposures for all 13 Swiss entities.	2.5	\$ 730	\$ 1,825.00
Marissa Low	02/28/20	Performed Manager review of the initial tax findings from the review of documentation prepared by S. Basak (KPMG) for two of the five Singapore entities	2.5	\$ 730	\$ 1,825.00
Devon Rowles	02/28/20	Updates to Purdue German structure deck with regards to asset/stock disposition analysis and tax consequences	3.1	\$ 350	\$ 1,085.00
Marissa Low	02/28/20	Performed Manager review of the initial tax findings from the review of documents prepared by S. Basak (KPMG) for the remaining three of the five Singapore entities	3.4	\$ 730	\$ 2,482.00

EXHIBIT C1

Purdue Pharma, L.P.

Case No. 19-23649

Bankruptcy Tax Consulting Services
February 1, 2020 through February 29, 2020
(includes time not previously billed)

Name	Date	Description	Hours	Rate	Amount
Jess Commisso	02/28/20	Performing updates to the cash tax model, specifically for Mundibiopharma Limited and Mundipharma Medical Company Limited, to incorporate correct distribution of cash to upper tier ownership and apply appropriate withholding rates.	3.9	\$ 350	\$ 1,365.00
Thomas Giordano	02/28/20	Revised the disposition scenario planning deck for UK subsidiary based on results of 2/28/2020 conference with I. Hirsch and P. DiMatteo (both KPMG).	3.9	\$ 350	\$ 1,365.00
Subtotal Tax Consulting Services					\$ 443,207.80
Credit related to updated KPMG India rates in KPMG's 1st monthly fee application					\$ (3,055.00)
Total Tax Consulting Services			931.7		\$ 440,152.80

EXHIBIT C2

Purdue Pharma, L.P.

Case No. 19-23649

Non -Working Travel Time

February 1, 2020 through February 29, 2020

Name	Date	Description	Hours	Rate	Amount
Isaac Hirsch	02/03/20	Non-working travel time for roundtrip travel from Short Hills, NJ to 560 Lexington Ave (KPMG NY office) for meeting with M&A team to walk through the Purdue cash tax model.	3.0	\$ 819	\$ 2,457.00
Subtotal Non-Working Travel Time			3.0		\$ 2,457.00
Less 50% Rate Reduction					\$ (1,228.50)
Less KPMG Voluntary Reduction					\$ (1,228.50) ⁽¹⁾
Total Non-Working Travel Time					\$ -

⁽¹⁾ KPMG is taking a voluntary reduction of non-working travel time.

EXHIBIT C3

Purdue Pharma, L.P.

Case No. 19-23649

Retention Services

February 1, 2020 through February 29, 2020

Name	Date	Description	Hours	Rate	Amount
Monica Plangman	02/18/20	(0.2) Perform research on docket regarding retention and upcoming hearing on 2/21/20 and provide results internally; (0.1) reach out to Debtors' counsel regarding attendance at hearing regarding retention; (0.2) address questions and request additional guidance in various emails with Debtors' counsel; (0.1) provide pertinent details to H. Steinberg regarding his attendance at 2/21/20 hearing and transmit pertinent documents.	0.6	\$ 264	\$ 158.40
Total Retention Services			<u>0.6</u>		<u>\$ 158.40</u>

EXHIBIT C4

Purdue Pharma, L.P.

Case No. 19-23649

Fee Application Preparation Services
February 1, 2020 through February 29, 2020

Name	Date	Description	Hours	Rate	Amount
Wendy Shaffer	02/03/20	0.2 Reviewed updated Work in Progress reports to confirm billable hours for Purdue Pharma through 1/31/2020	0.2	\$ 202	\$ 40.40
Wendy Shaffer	02/03/20	0.7 Created additional templates to be sent to 3 additional foreign member firms that includes bankruptcy time/expense keeping protocols to facilitate billing of services in the monthly fee applications.	0.7	\$ 202	\$ 141.40
Wendy Shaffer	02/04/20	Updated exhibit C1 of Purdue Pharma 1st monthly fee statement to include data received from professionals as of 2/4/2020	0.6	\$ 202	\$ 121.20
Wendy Shaffer	02/06/20	Updated exhibit C1 of Purdue Pharma 1st monthly fee statement to include data received from professionals as of 2/6/2020	3.8	\$ 202	\$ 767.60
Wendy Shaffer	02/07/20	3.5 Updated exhibit C1 of Purdue Pharma 1st monthly fee statement to include data received from professionals as of 2/7/2020; 0.3 Updated exhibit C4 of Purdue Pharma 1st monthly fee statement to include data received from professionals as of 2/7/2020	3.8	\$ 202	\$ 767.60
Wendy Shaffer	02/10/20	3.1 Updated exhibit C1 of Purdue Pharma 1st monthly fee statement to include data received from professionals as of 2/10/2020	3.1	\$ 202	\$ 626.20
Wendy Shaffer	02/11/20	Updated exhibit C1 of Purdue Pharma 1st monthly fee statement to include data received from professionals as of 2/11/2020	3.5	\$ 202	\$ 707.00
Wendy Shaffer	02/17/20	0.3 Updated exhibit D/ D1 of Purdue 1st monthly fee statement to include expense data received from professionals as of 2/17; 0.1 Reviewed updated Work in Progress report to confirm billable hours for Purdue Pharma from 12/23 through 1/31; 3.1 Updates to Purdue Pharma 1st monthly fee statement to include data received from professionals as of 2/17.	3.5	\$ 202	\$ 707.00
Wendy Shaffer	02/18/20	0.1 Communication via email with C. Nunez (KPMG) regarding status of Purdue 1st monthly fee statement and next steps; 3.0 Updates to exhibit C1 of Purdue Pharma 1st monthly fee statement to include data received from KPMG foreign member firms as of 2/21/2020	3.1	\$ 202	\$ 626.20
Wendy Shaffer	02/19/20	Updates to exhibit C1 of Purdue Pharma 1st monthly fee statement to include data received from professionals as of 2/19/20	0.8	\$ 202	\$ 161.60
Wendy Shaffer	02/24/20	1.2 Updated Purdue February fee statement exhibits to include services provided by KPMG foreign member firms as of 2/24/2020.	1.2	\$ 202	\$ 242.40

EXHIBIT C4

Purdue Pharma, L.P.

Case No. 19-23649

Fee Application Preparation Services
February 1, 2020 through February 29, 2020

Name	Date	Description	Hours	Rate	Amount
Wendy Shaffer	02/25/20	0.7 Updated Purdue February fee statement exhibits to include services provided by KPMG foreign member firms as of 2/28/2020; 0.2 being to create cover sheet for Purdue Pharma 1st monthly fee statement; 0.8 finalized Purdue Pharma 1st monthly fee statement exhibits and send to M. Plangman (KPMG) for initial review; 0.1 draft email to H. Steinberg (KPMG) regarding missing time detail; 0.2 email to C. Nunez (KPMG) regarding status of Purdue Pharma 1st monthly fee statement and info related to go forward procedures in the SD of NY.	2.0	\$ 202	\$ 404.00
Monica Plangman	02/25/20	Performed Associate Director review of fee statement and concurrently provide comments regarding expenses (0.5); Exhibit A (0.4) and C1 (2.6)	3.5	\$ 264	\$ 924.00
Monica Plangman	02/26/20	2.1 Continue associate director review of fee statement and concurrently provide comments; 0.2 call with W. Shaffer (KPMG) regarding go-forward with filing fee statement and contact with Debtors' counsel; 0.1 provide additional detail to W. Shaffer regarding billing process.	2.4	\$ 264	\$ 633.60
Wendy Shaffer	02/26/20	0.2 Communication via email with C. Nunez (KPMG) regarding status of Purdue Pharma 1st monthly fee statement and next steps to address outstanding items related to same. 0.2 Drafted email to KPMG Partners/ team leads to request review/approval of Purdue Pharma 1st monthly fee statement exhibits; 0.2 communication via email with D. Brogan (Bayard Law) S. Brauner (Akin) to request details regarding go forward to file and serve Purdue Pharma 1st monthly fee statement with regards to Joint Retention; 2.1 begin to draft Purdue Pharma 1st Interim fee statement documents; 0.1 created template for KPMG Singapore to capture time / expense detail to be billed in the bankruptcy court; 0.1 drafted email to KPMG Singapore team to provide template and the US bankruptcy time / expense keeping guidelines to facilitate billings in the bankruptcy court	2.9	\$ 202	\$ 585.80
Wendy Shaffer	02/26/20	0.2 Call with M. Plangman (KPMG) regarding next steps to finalize the Purdue Pharma 1st fee statement including communication required with counsel regarding process to file fee apps with regards to Joint retention; 0.7 call with M. Plangman (KPMG) regarding outstanding questions related to director review comments related to Purdue Pharma 1st monthly fee statement; 2.4 Updates to Purdue Pharma 1st monthly fee statement per direction from M. Plangman (KPMG)	3.3	\$ 202	\$ 666.60
Monica Plangman	02/27/20	0.1 Review document specifically regarding C1 and 0.2 discussion with W. Shaffer (KPMG) regarding same; review email from H. Steinberg (KPMG) regarding monthly fee statement and advise on go-forward 0.1	0.4	\$ 264	\$ 105.60

EXHIBIT C4

Purdue Pharma, L.P.

Case No. 19-23649

Fee Application Preparation Services
February 1, 2020 through February 29, 2020

Name	Date	Description	Hours	Rate	Amount
Wendy Shaffer	02/27/20	1.0 Updates to Purdue Pharma 1st monthly fee statement to include data received from KPMG Canadian professionals as of 2/27; 0.2 call with M. Plangman (KPMG) regarding questions related to updates requested to Purdue Pharma 1st monthly fee statement per M. Land (KPMG); 0.8 Additional updates to Purdue 1st monthly fee statement per management review comments received; 0.1 call with M. Land (KPMG) regarding questions regarding services performed by KPMG Canada to be included in 1st monthly fee statement.	2.1	\$ 202	\$ 424.20
Monica Plangman	02/28/20	Review revised first monthly fee statement documents and concurrently provide comments (0.4); review cover sheet and provide approval (0.1); review emails received regarding fee statement documents (0.1)	0.6	\$ 264	\$ 158.40
Wendy Shaffer	02/28/20	1.0 Additional updates to Purdue Pharma 1st monthly fee statement exhibits C1 per direction from C. Land (KPMG); 0.1 send copy of updated exhibits to C. Land (KPMG) for approval; 0.1 finalized Purdue Pharma 1st monthly fee statement cover sheet and 0.1 send to M. Plangman (KPMG) for review/approval; 0.1 drafted email to D. Consola (Davis Polk) with introduction and update regarding status of KPMG's 1st monthly fee statement and 1st Interim statement	1.4	\$ 202	\$ 282.80
Wendy Shaffer	02/28/20	0.2 Updates to Purdue Pharma 1st monthly fee statement per direction from D. Krishnamurthy (KPMG Manager); 1.1 finalization of Purdue Pharma 1st monthly fee statement; 0.2 draft email to H. Steinberg (KPMG) to request approval/permission to apply electronic signature to final draft of Purdue Pharma 1st monthly fee statement documents; 0.1 update and send KPMG foreign member from time detail submission email.	1.6	\$ 202	\$ 323.20
Total Fee Application Preparation Services			44.5		\$ 9,416.80

EXHIBIT D

Purdue Pharma, L.P.
Case No. 19-23649

Summary of Out of Pocket Expenses
February 1, 2020 through February 29, 2020

Category	Amount
Airfare	\$ -
Lodging	\$ -
Meals	\$ 58.13
Ground Transportation	\$ 607.18
Miscellaneous	\$ -
Expense Subtotal	\$ 665.31
Less KPMG Voluntary Reduction as noted on Exhibit D1	\$ (143.09)
Total	\$ 522.22

EXHIBIT D1

Purdue Pharma, L.P.

Case No. 19-23649

Detail of Out of Pocket Expenses
February 1, 2020 through February 29, 2020
(includes expenses not previously billed)

Name	Date	Description	Amount
Air Fare Subtotal			\$ -
Lodging Subtotal			\$ -
Devon Rowles	02/12/20	Fee for Business meals while performing services for Purdue Pharma; KPMG Participants: D. Rowles, J. Commisso	\$ 6.75 ⁽¹⁾
Devon Rowles	02/12/20	Business meals while performing services for Purdue Pharma. KPMG Participants: A. Armfield, D. Rowles, J. Commisso and M. Land	\$ 12.25 ⁽¹⁾
Ashley Armfield	02/19/20	Fee for Overtime meal incurred while working for Purdue Pharma. KPMG Participants: A. Armfield and J. Commisso	\$ 23.94 ⁽¹⁾
Devon Rowles	02/27/20	Fee for Business meals while performing services for Purdue bankruptcy. KPMG Participants: A. Armfield, D. Rowles, J. Commisso and M. Land	\$ 15.19 ⁽¹⁾
Meals Subtotal			\$ 58.13
Isaac Hirsch	01/27/20	Mileage in excess of normal commute for travel from the short hills (home office) to the 560 Lexington Avenue office to attend meeting with M&A team to discuss updates to cash tax model and related analysis	\$ 18.98 ⁽¹⁾
Pete DiMatteo	01/27/20	Fee for travel from NJ Transit train to/from Madison, NJ and KPMG NYC office to perform services for Purdue.	\$ 23.50 ⁽¹⁾
Isaac Hirsch	02/03/20	Mileage in excess of normal commute for travel from the short hills (home office) to the 560 Lexington Avenue office to attend meeting with M&A team to discuss updates to cash tax model and related analysis	\$ 18.98 ⁽¹⁾
Pete DiMatteo	02/03/20	Uber from NYC to home due to NJ Transit issues (split uber with a fellow professional)	\$ 82.68
Pete DiMatteo	02/03/20	Fee for NJ Transit train to/from Madison, NJ and KPMG NYC office to perform services for Purdue.	\$ 23.50 ⁽¹⁾
Isaac Hirsch	02/20/20	Lyft fee (one way) in the evening for travel from NY office to home in Livingston, NJ following meeting related to Purdue cash tax model and related analyses	\$ 131.62
Isaac Hirsch	02/20/20	Lyft fee (one way) in the morning for travel from home in Livingston, NJ to KPMG NY office to meet with M&A team on the cash tax model and related analyses	\$ 102.51
Howard Steinberg	02/21/20	Uber fee incurred for travel from home in New York City to Bankruptcy Court on 2-21-20 to attend Purdue Hearing	\$ 83.21
Howard Steinberg	02/21/20	Uber fee incurred for travel from Bankruptcy Court to KPMG office following attendance at Purdue Hearing on 2-21-20	\$ 122.20
Total Ground Transportation			\$ 607.18
Miscellaneous Subtotal			\$ -
Subtotal Out of Pocket Expenses			\$ 665.31
Less KPMG Voluntary Reduction			\$ (143.09) ⁽¹⁾
Total Out of Pocket Expenses			\$ 522.22

⁽¹⁾ KPMG is taking a voluntary reduction of expenses under \$50.00.